1
|
Moutapam-Ngamby-Adriaansen Y, Maillot F, Labarthe F, Lioger B. Blood cytopenias as manifestations of inherited metabolic diseases: a narrative review. Orphanet J Rare Dis 2024; 19:65. [PMID: 38355710 PMCID: PMC10865644 DOI: 10.1186/s13023-024-03074-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Accepted: 02/03/2024] [Indexed: 02/16/2024] Open
Abstract
Inherited Metabolic Diseases (IMD) encompass a diverse group of rare genetic conditions that, despite their individual rarity, collectively affect a substantial proportion, estimated at as much as 1 in 784 live births. Among their wide-ranging clinical manifestations, cytopenia stands out as a prominent feature. Consequently, IMD should be considered a potential diagnosis when evaluating patients presenting with cytopenia. However, it is essential to note that the existing scientific literature pertaining to the link between IMD and cytopenia is limited, primarily comprising case reports and case series. This paucity of data may contribute to the inadequate recognition of the association between IMD and cytopenia, potentially leading to underdiagnosis. In this review, we synthesize our findings from a literature analysis along with our clinical expertise to offer a comprehensive insight into the clinical presentation of IMD cases associated with cytopenia. Furthermore, we introduce a structured diagnostic approach underpinned by decision-making algorithms, with the aim of enhancing the early identification and management of IMD-related cytopenia.
Collapse
Affiliation(s)
- Yannick Moutapam-Ngamby-Adriaansen
- Service de Médecine Interne, CHRU de Tours, Tours Cedex 1, France.
- Service de Médecine Interne Et Polyvalente, 2, Centre Hospitalier de Blois, Mail Pierre Charlot, 41000, Blois, France.
| | - François Maillot
- Service de Médecine Interne, CHRU de Tours, Tours Cedex 1, France
- Reference Center for Inborn Errors of Metabolism ToTeM, CHRU de Tours, Hôpital Clocheville, 49 Bd Béranger, 37000, Tours, France
- INSERM U1253, iBrain, Université François Rabelais de Tours, 10 Boulevard Tonnellé, 37000, Tours, France
- INSERM U1069, Nutrition, Croissance et Cancer, Faculté de Médecine, Université François Rabelais de Tours, 10 Boulevard Tonnellé, 37000, Tours, France
| | - François Labarthe
- Reference Center for Inborn Errors of Metabolism ToTeM, CHRU de Tours, Hôpital Clocheville, 49 Bd Béranger, 37000, Tours, France
- INSERM U1069, Nutrition, Croissance et Cancer, Faculté de Médecine, Université François Rabelais de Tours, 10 Boulevard Tonnellé, 37000, Tours, France
- Service de Pédiatrie, CHRU de Tours, Tours Cedex 1, France
| | - Bertrand Lioger
- Service de Médecine Interne Et Polyvalente, 2, Centre Hospitalier de Blois, Mail Pierre Charlot, 41000, Blois, France
| |
Collapse
|
2
|
Mekinian A, Biard L, Lorenzo D, Novikov PI, Salvarani C, Espitia O, Sciascia S, Michaud M, Lambert M, Hernández-Rodríguez J, Schleinitz N, Awisat A, Puechal X, Aouba A, Munoz Pons H, Smitienko I, Gaultier JB, Edwige LM, Benhamou Y, Perlat A, Jego P, Goulenok T, Sacre K, Lioger B, Hassold N, Broner J, Dufrost V, Sené T, Seguier J, Maurier F, Berthier S, Belot A, Frikha F, Denis G, Audemard-Verger A, Koné-Paut I, Humbert S, Woaye-Hune P, Tomelleri A, Baldissera EM, Kuwana M, Logullo A, Mukuchyan V, Dellal A, Gaches F, Zeminsky P, Galli E, Alvarado M, Boiardi L, Francesco M, Vautier M, Corrado C, Moiseev S, Vieira M, Cacoub P, Fain O, Saadoun D. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study. RMD Open 2023; 9:e002830. [PMID: 37321669 DOI: 10.1136/rmdopen-2022-002830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Accepted: 02/02/2023] [Indexed: 06/17/2023] Open
Abstract
OBJECTIVES In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients. METHODS We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019. RESULTS A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Among them, 91 and 18 patients received intravenous and SC tocilizumab, respectively. A complete response (NIH <2 with less than 7.5 mg/day of prednisone) at 6 months was evidenced in 69% of TAK patients, of whom 57 (70%) and 11 (69%) patients were on intravenous and SC tocilizumab, respectively (p=0.95). The factors associated with complete response to tocilizumab at 6 months in multivariate analysis, only age <30 years (OR 2.85, 95% CI 1.14 to 7.12; p=0.027) and time between TAK diagnosis and tocilizumab initiation (OR 1.18, 95% CI 1.02 to 1.36; p=0.034). During the median follow-up of 30.1 months (0.4; 105.8) and 10.8 (0.1; 46.4) (p<0.0001) in patients who received tocilizumab in intravenous and SC forms, respectively, the risk of relapse was significantly higher in TAK patients on SC tocilizumab (HR=2.55, 95% CI 1.08 to 6.02; p=0.033). The overall cumulative incidence of relapse at 12 months in TAK patients was at 13.7% (95% CI 7.6% to 21.5%), with 10.3% (95% CI 4.8% to 18.4%) for those on intravenous tocilizumab vs 30.9% (95% CI 10.5% to 54.2%) for patients receiving SC tocilizumab. Adverse events occurred in 14 (15%) patients on intravenous route and in 2 (11%) on SC tocilizumab. CONCLUSION In this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months.
Collapse
Affiliation(s)
- Arsène Mekinian
- Sorbonne Université, AP-HP, Hôpital Saint Antoine, Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), F-75012, Paris, France, French Armenian research center, Erevan, Armenia
| | - Lucie Biard
- Université de Paris, AP-HP, Hôpital Saint Louis, Service de Biostatistique et Information Médicale (DMU PRISME), INSERM U1153 Team ECSTRRA, Paris, France
| | - Dagna Lorenzo
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - Pavel I Novikov
- Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | - Carlo Salvarani
- Azienda USL-IRCCS; Division of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy
| | - Olivier Espitia
- Department of internal and vascular medicine, Nantes Université, CHU Nantes, F-44000 Nantes, France
| | - Savino Sciascia
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Aosta Valley Network for Rare Diseases, Nephrology and Dialysis, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Martin Michaud
- Médecine Interne, Hôpital Joseph Ducuing, Toulouse, France
| | - Marc Lambert
- Univ. Lille, CHU Lille, Département de Médecine Interne et d'Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares Nord et Nord-Ouest de France (CeRAINO), European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNECT), INSERM, UMR 1167, RID-AGE, Lille, France
| | - José Hernández-Rodríguez
- Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | | | - Abid Awisat
- Rheumatology Unit, Bnei Zion Hospital, Haifa, Israel
| | - Xavier Puechal
- Université Paris Descartes, Paris, France ; AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, Service de médecine interne, 27 rue du Faubourg Saint-Jacques, Paris, France
| | - Achille Aouba
- Département de médecine interne, CHU Caen, Caen, France
| | - Helene Munoz Pons
- Département de médecine interne, CHU Saint Etienne, Saint-Etienne, France
| | - Ilya Smitienko
- Rheumatology Department, Medical Center K-31, Moscow, Russian Federation
| | - Jean Baptiste Gaultier
- Service de Médecine Interne, Hôpital Nord, Centre Hospitalier universitaire de St Etienne, Saint Etienne, France
| | - Le Mouel Edwige
- Internal Medicine and Clinical Immunology Department, CHU Rennes, Universitaire de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France
| | - Ygal Benhamou
- Service de médecine interne, Université Rouen, CHU de Rouen, Rouen, France
| | - Antoinette Perlat
- Internal Medicine and Clinical Immunology Department, CHU Rennes, Universitaire de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France
| | - Patrick Jego
- Internal Medicine and Clinical Immunology Department, CHU Rennes, Universitaire de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France
| | - Tiphaine Goulenok
- Département de Médecine Interne, Hôpital Bichat, Université de Paris, Assistance Publique Hôpitaux de Paris, INSERM U1149, Paris, France
| | - Karim Sacre
- Département de Médecine Interne, Hôpital Bichat, Université de Paris, Assistance Publique Hôpitaux de Paris, INSERM U1149, Paris, France
| | | | - Nolan Hassold
- Service de Rhumatologie pédiatrique et centre de référence des maladies autoinflammatoires et de l'amylose inflammatoire, CEREMAIA, hôpital de Bicêtre, APHP, France, université de Paris Sud-Saclay, Paris, France
| | | | - Virginie Dufrost
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, University of Lorraine, Inserm UMR_S 1116, CHRU de Nancy, Nancy, France
| | - Thomas Sené
- Service de médecine interne, Rothschild, Paris, France
| | - Julie Seguier
- Département de médecine interne, CHU de La Timone, Marseille, France
| | - Francois Maurier
- Service de Médecine Interne et Immunologie Clinique Groupe Hospitalier UNEOS, Vantoux, France
| | - Sabine Berthier
- Service de médecine interne et immunologie clinique, Université Dijon, Hôpital Dijon, Dijon, France
| | - Alexandre Belot
- Service de pédiatrie et immunologie clinique, Université Lyon, Hôpital Lyon, Lyon, France
| | - Faten Frikha
- Service de Médecine interne CHU Hédi Chaker, Route El Ain 3029 Sfax -Faculté de Médecine de Sfax, Sfax, Tunisia
| | - Guillaume Denis
- Service de médecine et d'hématologie, Hopital Rochefort, Rochefort, France
| | - Alexandra Audemard-Verger
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, University of Tours, Tours, France
| | - Isabelle Koné-Paut
- Service de Rhumatologie pédiatrique et centre de référence des maladies autoinflammatoires et de l'amylose inflammatoire, CEREMAIA, hôpital de Bicêtre, APHP, France, université de Paris Sud-Saclay, Paris, France
| | - Sebastien Humbert
- Service de médecine interne et immunologie clinique, Hôpital Besancon, Besancon, France
| | | | - Alessandro Tomelleri
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - Elena Marina Baldissera
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - Masataka Kuwana
- Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
| | - Alberto Logullo
- IRCCS Centro Neurolesi "Bonino-Pulejo", Ospedale Piemonte, Messina, Italy
| | - Vahan Mukuchyan
- Department of Internal Medicine and Rheumatology, Nairi hospital, Erevan, Armenia
| | - Azeddine Dellal
- Service de rhumatologie, Hôpital Montfermeil, GHI Le Raincy Montfermeil, Montfermeil, France
| | - Francis Gaches
- Médecine Interne, Hôpital Joseph Ducuing, Toulouse, France
| | - Pierre Zeminsky
- Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, University of Lorraine, Inserm UMR_S 1116, CHRU de Nancy, Nancy, France
| | - Elena Galli
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - Moya Alvarado
- Azienda USL-IRCCS; Division of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy
| | - Luigi Boiardi
- Azienda USL-IRCCS; Division of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy
| | - Muratore Francesco
- Azienda USL-IRCCS; Division of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy
| | - Mathieu Vautier
- Université de Paris, AP-HP, Hôpital Saint Louis, Service de Biostatistique et Information Médicale (DMU PRISME), INSERM U1153 Team ECSTRRA, Paris, France
| | - Campochiaro Corrado
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - Sergey Moiseev
- Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | - Matheus Vieira
- AP-HP, Hôpital Pitié Salpetrière, Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Universités, Paris, France
| | - Patrice Cacoub
- AP-HP, Hôpital Pitié Salpetrière, Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Universités, Paris, France
| | - Olivier Fain
- Sorbonne Université, AP-HP, Hôpital Saint Antoine, Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), F-75012, Paris, France, French Armenian research center, Erevan, Armenia
| | - David Saadoun
- AP-HP, Hôpital Pitié Salpetrière, Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Universités, Paris, France
| |
Collapse
|
3
|
Loiret L, Marquet L, Lioger B, Stankovic Stojanovic K. Partenariat patient : partage d’expérience dans le cas d’une crise vaso-occlusive drépanocytaire. La Revue de l'Infirmière 2023; 72:45-48. [PMID: 37024197 DOI: 10.1016/j.revinf.2023.02.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/18/2023]
Abstract
The patient partnership is a new approach in which the patient, through his knowledge acquired from his experience with the disease, is a stakeholder in decisions about care, the organization of the health system and choices in terms of health policy. A team from the Blois hospital (41) was able to share the experience of a patient partnership during the analysis of a complex medical situation with a young man with sickle cell disease in a vaso-occlusive crisis. She reports here this new and enriching experience.
Collapse
|
4
|
Perez Y, Belmatoug N, Bengherbia M, Yousfi K, Lioger B. [Misdiagnosis of Gaucher disease in real life: Retrospective study of the French Gaucher's disease registry]. Rev Med Interne 2023; 44:55-61. [PMID: 36669934 DOI: 10.1016/j.revmed.2022.11.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 11/14/2022] [Accepted: 11/30/2022] [Indexed: 01/20/2023]
Abstract
INTRODUCTION Gaucher disease is an autosomal recessive genetic disorder. It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase which leads to an accumulation of glucosylceramide in the macrophages. Splenomegaly, hepatomegaly, cytopenias (anemia, thrombocytopenia) and bone disorders are the main symptoms. The diagnosis is often delayed, leading to unnecessary investigations and treatments, and delaying the specific treatment. The primary objective of our study was to establish, in patients who had a diagnostic delay of more than one year, the reported misdiagnoses before the final diagnosis. The secondary objectives were to investigate the risk factors associated with error and delayed diagnosis. METHODS Retrospective study including patients with Gaucher disease from the French Gaucher Disease Registry. Collection of data by a single investigator from a standardized form. RESULTS Among 83 patients with a known diagnostic delay, 13 patients (15 %) had one or two misdiagnoses. These included osteo-articular diagnoses (osteomyelitis, osteoarthritis, arthritis, osteochondritis, rheumatic fever, n=8), haematological diagnoses (gestational thrombocytopenia, immunological thrombocytopenia, n=4), infectious diagnoses (visceral leishmaniasis, mononucleosis, n=2) and hemochromatosis. The osteo-articular and infectious diagnoses concerned the child and the adolescent while the haematological diagnoses and the hemochromatosis concerned the adult. No factors were found associated with misdiagnoses. Patients with a diagnostic delay greater than one year were less likely to have hepatosplenomegaly as the first symptom. CONCLUSION There is a risk of diagnostic error related to phenotypic heterogeneity and lack of specificity of Gaucher disease symptoms. This study helps to better identify the misdiagnoses associated with Gaucher disease.
Collapse
Affiliation(s)
- Y Perez
- Service de médecine interne, CHRU de Tours, 2 boulevard Tonnelé, 37044 Tours cedex, France.
| | - N Belmatoug
- Centre de référence des maladies lysosomales, hôpitaux universitaires Paris Nord-Val-de-Seine, CHU Paris Nord-Val de Seine, hôpital Beaujon, Assistance publique-Hôpitaux de Paris (AP-HP), 100, boulevard du Général-Leclerc, 92110 Clichy, France; Service de médecine interne, hôpital Beaujon, Paris, France
| | - M Bengherbia
- Centre de référence des maladies lysosomales, hôpitaux universitaires Paris Nord-Val-de-Seine, CHU Paris Nord-Val de Seine, hôpital Beaujon, Assistance publique-Hôpitaux de Paris (AP-HP), 100, boulevard du Général-Leclerc, 92110 Clichy, France; Service de médecine interne, hôpital Beaujon, Paris, France
| | - K Yousfi
- Centre de référence des maladies lysosomales, hôpitaux universitaires Paris Nord-Val-de-Seine, CHU Paris Nord-Val de Seine, hôpital Beaujon, Assistance publique-Hôpitaux de Paris (AP-HP), 100, boulevard du Général-Leclerc, 92110 Clichy, France; Service de médecine interne, hôpital Beaujon, Paris, France
| | - B Lioger
- Service de médecine interne et polyvalente, centre hospitalier Simone Veil, 1 mail Pierre-Charlot, Blois, France
| |
Collapse
|
5
|
Guillet S, Loustau V, Boutin E, Zarour A, Comont T, Souchaud-Debouverie O, Costedoat Chalumeau N, Pan-Petesch B, Gobert D, Cheze S, Viallard JF, Morin AS, Sauvetre G, Cliquennois M, Royer B, Masseau A, Terriou L, Fieschi C, Lambotte O, Girault S, Lioger B, Audia S, Sacre K, Lega JC, Langlois V, Benachi A, Orvain C, Devidas A, Humbert S, Gambier N, Ruivard M, Zarrouk V, Ebbo M, Willems L, Segaux L, Mahevas M, Haddad B, Michel M, Canoui-Poitrine F, Godeau B. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study. Blood 2023; 141:11-21. [PMID: 36054922 PMCID: PMC10644036 DOI: 10.1182/blood.2022017277] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 07/18/2022] [Accepted: 08/03/2022] [Indexed: 01/10/2023] Open
Abstract
The risk of immune thrombocytopenia (ITP) worsening during pregnancy and neonatal ITP (NITP) have never been prospectively studied. We included 180 pregnant and 168 nonpregnant women with ITP in a prospective, multicenter, observational cohort study. A total of 131 pregnant women with ITP were matched to 131 nonpregnant women with ITP by history of splenectomy, ITP status (no response, response, complete response), and duration. Groups were followed for 15 months. The primary outcome was the first occurrence of ITP worsening defined by a composite end point including bleeding events and/or severe thrombocytopenia (<30 × 109/L) and/or ITP treatment modification. We also studied the recurrence of ITP worsening and the incidence of NITP and risk factors. The first occurrence of ITP worsening did not differ between pregnant and nonpregnant women with ITP (53.4 per 100 person-years [95% confidence interval {CI}, 40.8-69.9] vs 37.1 [95% CI, 27.5-50.0]; hazard ratio {HR}, 1.35 [95% CI, 0.89-2.03], P = .16). Pregnant women with ITP were more likely to have recurrence of severe thrombocytopenia and treatment modification (HR, 2.71 [95% CI, 1.41-5.23], P = .003; HR, 2.01 [95% CI, 1.14-3.57], P = .017, respectively). However, recurrence of severe bleeding events was not different between groups (P = .4). Nineteen (14%) neonates showed NITP <50 × 109/L. By multivariable analysis, NITP was associated with a previous offspring with NITP and maternal platelet count <50 × 109/L within 3 months before delivery (adjusted odds ratio, 5.55 [95% CI, 1.72-17.89], P = .004 and 4.07 [95% CI, 1.41-11.73], P = .009). To conclude, women with ITP do not increase their risk of severe bleeding during pregnancy. NITP is associated with NITP history and the severity of maternal ITP during pregnancy. These results will be useful for counseling women with ITP.
Collapse
MESH Headings
- Infant, Newborn
- Female
- Humans
- Pregnancy
- Purpura, Thrombocytopenic, Idiopathic/epidemiology
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Purpura, Thrombocytopenic, Idiopathic/complications
- Cohort Studies
- Prospective Studies
- Pregnancy Complications, Hematologic/epidemiology
- Pregnancy Complications, Hematologic/therapy
- Thrombocytopenia, Neonatal Alloimmune/therapy
- Retrospective Studies
Collapse
Affiliation(s)
- Stéphanie Guillet
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| | - Valentine Loustau
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
- Service de Médecine Interne, Centre Hospitalier Alpes Léman, Contamine sur Arve, France
| | - Emmanuelle Boutin
- Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
- Univ Paris Est Créteil, INSERM, IMRB, Equipe CEpiA (Clinical Epidemiology and Ageing), Créteil, France
| | - Anissa Zarour
- Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Thibault Comont
- Service de Médecine Interne et d’Immunopathologie–IUCT-Oncopole, CHU de Toulouse, Toulouse, France
| | | | - Nathalie Costedoat Chalumeau
- Service de Médecine Interne, Centre de Référence Maladies Auto-immunes et Systémiques Rares, Hôpital Cochin, AP-HP, Université de Paris, Paris, France
- Centre for Clinical Epidemiology, Hôpital Hôtel-Dieu, AP-HP, Université de Paris, Centre of Research in Epidemiology and Statistics, Paris, France
| | | | - Delphine Gobert
- Service de Médecine Interne, Hôpital Saint Antoine, AP-HP, Sorbonne Université, Paris, France
| | - Stéphane Cheze
- Institut d’Hématologie de Basse-Normandie, Centre Hospitalier de Caen Normandie, Caen, France
| | | | - Anne-Sophie Morin
- Service de Médecine Interne, Hôpital Jean Verdier, AP-HP, Bondy, France
| | - Gaetan Sauvetre
- Service de Médecine Interne, Hôpital Charles Nicolle, Université de Rouen, Rouen, France
| | - Manuel Cliquennois
- Service d'Onco-hématologie Adulte, Hôpital Saint-Vincent de Paul, GH de l'institut Catholique de Lille, Lille, France
| | - Bruno Royer
- Service d’Immuno-hématologie, Hôpital Saint Louis, Paris, France
- Service d’Hématologie clinique, CHU d’Amiens, Amiens, France
| | - Agathe Masseau
- Service de Médecine Interne, CHU de Nantes, Nantes, France
| | - Louis Terriou
- Service de Médecine Interne et d’Immunologie Clinique, CHU Lille, Université de Lille, Lille, France
| | - Claire Fieschi
- Service d’Immunologie Clinique, Hôpital Saint Louis, AP-HP, Paris, France
| | - Olivier Lambotte
- Service de Médecine Interne et d’Immunologie Clinique, Hôpital Bicêtre, Université Paris Sacly, Le Kremlin-Bicêtre, France
| | - Stéphane Girault
- Service d’Hématologie Clinique et de Thérapie Cellulaire, CHU Dupuytren, Limoges, France
| | | | - Sylvain Audia
- Service de Médecine Interne et d’Immunologie Clinique, Centre de Référence Constitutif des Cytopénies Auto-Immunes, Hôpital François Mitterrand, CHU Dijon-Bourgogne, Dijon, France
| | - Karim Sacre
- Service de Médecine Interne, Hôpital Bichat, AP-HP, Paris, France et Université de Paris, Centre de Recherche sur l’Inflammation, INSERM UMR1149, CNRS ERL8252, Laboratoire d’Excellence Inflamex, Paris, France
| | - Jean Christophe Lega
- Service de Médecine Interne et Médecine Vasculaire, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, Université de Lyon, Lyon, France
- Laboratoire de Biométrie et Biologie Évolutive, CNRS-UMR 5588, Université Lyon 1, Lyon, France
| | - Vincent Langlois
- Service de Médecine Interne, Hôpital Jacques Monod, Le Havre, France
| | - Alexandra Benachi
- Service d’Obstétrique et Gynécologie, Hôpital Antoine-Béclère, AP-HP, Université Paris-Saclay, Clamart, France
| | - Corentin Orvain
- Service d’Hématologie, Hôpital d’Anger, INSERM, CRCINA, Université d’Angers, Angers, France
| | - Alain Devidas
- Service d’Hématologie Clinique, CH Sud Francilien, Corbeil Essonnes, France
| | | | - Nicolas Gambier
- Service de Médecine Interne, CH Général Delafontaine, St Denis, France
| | - Marc Ruivard
- Service de Médecine Interne, CHU Estaing, Clermont-Ferrand, France
| | - Virginie Zarrouk
- Service de Médecine Interne, Hôpital Beaujon, AP-HP, Clichy, France
| | - Mikael Ebbo
- Service de Médecine Interne, Hôpital de la Conception, AP-HP, Université Aix-Marseille, Marseille, France
| | - Lise Willems
- Service d’Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Lauriane Segaux
- Service de Santé Publique, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Matthieu Mahevas
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| | - Bassam Haddad
- Centre Hospitalier Inter-Communal de Créteil, Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Equipe Immunorégulation et Biothérapie (I-BIOT), Université Paris Est Créteil, Univ Paris Est Créteil, INSERM U955, Institut Mondor De Recherche Biomédicale (IMRB), Créteil, France
| | - Marc Michel
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| | - Florence Canoui-Poitrine
- Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
- Service de Santé Publique, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Bertrand Godeau
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| |
Collapse
|
6
|
Zuelgaray E, Chevret S, Jachiet M, Cacoub P, Kahn JE, Groh M, Granel B, Scafi M, Geffray L, Chasset F, Gatfosse M, Mekinian A, Lioger B, Mahr A, Gaches F, Michaud M, Ludot I, Cordoliani F, de Masson A, Cassius C, Retornaz F, Audemard-Verger A, Lartigau-Roussin C, Roriz M, Chaigne B, Pallure V, Marie I, Castel B, Loustau V, Chiche L, Gavand PE, Cathebras P, Barete S, Frances C, Brenaut E, Allenbach Y, Benveniste O, Noel N, Urbanski G, Hinschberger O, Bessis D, Bagot M, Bouaziz JD, Sène D. Trunk involvement and peau d'orange aspect are poor prognostic factors in eosinophilic fasciitis (Shulman disease): A multicenter retrospective study of 119 patients. J Am Acad Dermatol 2023; 88:160-163. [PMID: 33188872 DOI: 10.1016/j.jaad.2020.11.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 11/05/2020] [Accepted: 11/05/2020] [Indexed: 11/28/2022]
Affiliation(s)
- Elina Zuelgaray
- Service de Dermatologie, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Sylvie Chevret
- Service de Biostatistique et Information Médicale, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Marie Jachiet
- Service de Dermatologie, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Patrice Cacoub
- Département de Médecine Interne et d'Immunologie clinique, Sorbonne-Université, Hôpital de la Pitié-Salpêtrière, APHP, Paris, France
| | - Jean-Emmanuel Kahn
- Centre National de Référence des Syndromes Hyperéosinophiliques, Service de Médecine Interne, Hôpital Foch, Suresnes, France
| | - Matthieu Groh
- Centre National de Référence des Syndromes Hyperéosinophiliques, Service de Médecine Interne, Hôpital Foch, Suresnes, France
| | - Brigitte Granel
- Service de Médecine Interne et d'Immunologie clinique, Hôpital Nord, Marseille, France
| | - Manon Scafi
- Service de Médecine Interne et d'Immunologie clinique, Hôpital Nord, Marseille, France
| | - Loïk Geffray
- Service de Médecine Interne et d'Immunologie clinique, Centre Hospitaliser de Lisieux, Lisieux, France
| | - François Chasset
- Service de Dermatologie, Université de Paris, Hôpital Tenon, Paris, France
| | - Marc Gatfosse
- Service de Médecine Interne et d'Immunologie clinique, Sorbonne Université, Hôpital Saint-Antoine, Paris, France
| | - Arsène Mekinian
- Service de Médecine Interne et d'Immunologie clinique, Sorbonne Université, Hôpital Saint-Antoine, Paris, France
| | - Bertrand Lioger
- Unité de Médecine Interne et Maladies systémiques, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Alfred Mahr
- Unité de Médecine Interne et Maladies systémiques, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Francis Gaches
- Service de Médecine Interne et d'Immunologie clinique, Hôpital Joseph Ducuing, Toulouse, France
| | - Martin Michaud
- Service de Médecine Interne et d'Immunologie clinique, Hôpital Joseph Ducuing, Toulouse, France
| | - Isabelle Ludot
- Service de Rhumatologie, Clinique Pasteur, Toulouse, France
| | - Florence Cordoliani
- Service de Dermatologie, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Adèle de Masson
- Service de Dermatologie, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Charles Cassius
- Service de Dermatologie, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Frédérique Retornaz
- Unité de soins et de recherche en médecine interne et de maladies infectieuses, Hôpital Européen, Marseille, France
| | - Alexandra Audemard-Verger
- Service de Médecine Interne et d'Immunologie clinique, Centre Hospitalo-Universitaire Côte de Nacre, Caen, France
| | - Céline Lartigau-Roussin
- Service de Médecine Interne et d'Immunologie clinique, Centre Hospitalier Ouest Réunion, Saint Paul, France
| | - Mélanie Roriz
- Service de Médecine Interne et d'Immunologie clinique, Hôpital Bichat, Paris, France
| | - Benjamin Chaigne
- Service de Médecine Interne et d'Immunologie clinique, Hôpital Cochin, Paris, France
| | - Valérie Pallure
- Service de Dermatologie, Centre Hospitalier de Perpignan, Perpignan, France
| | - Isabelle Marie
- Service de Médecine Interne et d'Immunologie clinique, Centre Hospitalo-Universitaire de Rouen, Rouen, France
| | - Brice Castel
- Service de Médecine Interne et d'Immunologie clinique, Centre Hospitalier de Lourdes, Lourdes, France
| | - Valentine Loustau
- Service de Médecine Interne et d'Immunologie clinique, Centre Hospitalier Alpes Léman, Contamine-sur-Avre, France
| | - Laurent Chiche
- Unité de soins et de recherche en médecine interne et de maladies infectieuses, Hôpital Européen, Marseille, France
| | - Pierre-Edouard Gavand
- Service de Médecine Interne et d'Immunologie clinique, Clinique Rhena, Strasbourg, France
| | - Pascal Cathebras
- Service de Médecine Interne et d'Immunologie clinique, Centre Hospitalo-Universitaire de Saint Etienne, Hôpital Nord, Saint-Etienne, France
| | - Stéphane Barete
- Service de Dermatologie, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Camille Frances
- Service de Dermatologie, Université de Paris, Hôpital Tenon, Paris, France
| | - Emilie Brenaut
- Service de Dermatologie, Centre Hospitalo-Universitaire Morvan, Brest, France
| | - Yves Allenbach
- Département de Médecine Interne et d'Immunologie clinique, Sorbonne-Université, Hôpital de la Pitié-Salpêtrière, APHP, Paris, France
| | - Olivier Benveniste
- Département de Médecine Interne et d'Immunologie clinique, Sorbonne-Université, Hôpital de la Pitié-Salpêtrière, APHP, Paris, France
| | - Nicolas Noel
- Service de Médecine Interne et d'Immunologie clinique, Hôpital Bicêtre, Kremlin-Bicêtre, France
| | - Geoffrey Urbanski
- Service de Médecine Interne et d'Immunologie clinique, Centre Hospitalo-Universitaire d'Angers, Angers, France
| | - Olivier Hinschberger
- Service de Médecine Interne et d'Immunologie clinique, Hôpital Emile Muller, Mulhouse, France
| | - Didier Bessis
- Service de Dermatologie, Hôpital Saint Eloi, Montpellier, France
| | - Martine Bagot
- Service de Dermatologie, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Jean-David Bouaziz
- Service de Dermatologie, Université de Paris, Hôpital Saint-Louis, Paris, France.
| | - Damien Sène
- Service de Médecine Interne et d'Immunologie clinique, Hôpital Lariboisière, Paris, France
| | | | | | | |
Collapse
|
7
|
Gay S, Lioger B, Kouchit Y, Decalonne L, Halimi J, Seitz-Polski B, Pillebout E, Ramdani Y, Maillot F, Alexandra A. Description d’une série de patients atteints de vascularite à IgA associée à des ANCA d’isotype IgA. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
8
|
Audemard-Verger A, Le Gouge A, Pestre V, Courjon J, Langlois V, Vareil MO, Devaux M, Bienvenu B, Leroy V, Goulabchand R, Colombain L, Bigot A, Guimard T, Douadi Y, Urbanski G, Faucher JF, Maulin L, Lioger B, Talarmin JP, Groh M, Emmerich J, Deriaz S, Ferreira-Maldent N, Cook AR, Lengellé C, Bourgoin H, Mekinian A, Aouba A, Maillot F, Caille A. Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial. PLoS One 2022; 17:e0269065. [PMID: 35925914 PMCID: PMC9351999 DOI: 10.1371/journal.pone.0269065] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Accepted: 05/12/2022] [Indexed: 01/08/2023] Open
Abstract
Objective We aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients. Methods In this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen. We randomly assigned patients to receive intravenous anakinra plus optimized standard of care (oSOC) vs. oSOC alone. The primary outcome was treatment success at day 14 defined as patient alive and not requiring mechanical ventilation or extracorporeal membrane oxygenation. Results Between 27th April and 6th October 2020, we enrolled 71 patients (240 patients planned to been enrolled): 37 were assigned to the anakinra group and 34 to oSOC group. The study ended prematurely by recommendation of the data and safety monitoring board due to safety concerns. On day 14, the proportion of treatment success was significantly lower in the anakinra group 70% (n = 26) vs. 91% (n = 31) in the oSOC group: risk difference—21 percentage points (95% CI, -39 to -2), odds ratio 0.23 (95% CI, 0.06 to 0.91), p = 0.027. After a 28-day follow-up, 9 patients in the anakinra group and 3 in the oSOC group had died. Overall survival at day 28 was 75% (95% CI, 62% to 91%) in the anakinra group versus 91% (95% CI, 82% to 100%) (p = 0.06) in the oSOC group. Serious adverse events occurred in 19 (51%) patients in the anakinra group and 18 (53%) in the oSOC group (p = 0·89). Conclusion This trial did not show efficacy of anakinra in patients with COVID-19. Furthermore, contrary to our hypothesis, we found that anakinra was inferior to oSOC in patients with moderate COVID-19 pneumonia.
Collapse
Affiliation(s)
- Alexandra Audemard-Verger
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
- University of Tours, Tours, France
- * E-mail:
| | | | - Vincent Pestre
- Department of Internal Medicine and Infectious Diseases, CH Avignon, Avignon, France
| | - Johan Courjon
- Department of Infectious Diseases, Université Côte d’Azur, CHU Nice, Nice, France
| | | | | | - Mathilde Devaux
- Department of Internal Medicine, CH de Poissy, Poissy, France
| | - Boris Bienvenu
- Department of Internal Medicine, Hôpital Saint Joseph, Marseille, France
| | - Vincent Leroy
- Department of Infectious Diseases, Clinique Tessier, Valenciennes, France
| | - Radjiv Goulabchand
- Internal Medicine Department & Department of Infectious and Tropical Diseases, Nîmes University Hospital, University of Montpellier, Nîmes, France
| | - Léa Colombain
- Department of Infectious Diseases, CH de Perpignan, Perpignan, France
| | - Adrien Bigot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Thomas Guimard
- Department of Infectious Diseases, CH la Roche sur Yon, La Roche sur Yon, France
| | - Youcef Douadi
- Department of Infectious Diseases, CH Saint Quentin, Saint Quentin, France
| | - Geoffrey Urbanski
- Department of Internal Medicine and Clinical Immunology, CHU Angers, Angers France
| | | | - Laurence Maulin
- Department of Infectious Diseases, CH Aix en Provence, Aix en Provence, France
| | | | | | - Matthieu Groh
- Department of Internal Medicine, Hôpital Foch, Suresnes, France
| | - Joseph Emmerich
- Department of Vascular Medicine, GH Saint Joseph and Université de Paris, INSERM CRESS 1153, Paris, France
| | - Sophie Deriaz
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | | | - Ann-Rose Cook
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | | | | | - Arsène Mekinian
- Department of Internal Medicine, Hôpital Saint Antoine, Sorbonne Université, Paris, France
| | - Achille Aouba
- Department of Internal Medicine, CHU de Caen, Caen, France
| | - François Maillot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
- University of Tours, Tours, France
| | - Agnès Caille
- University of Tours, Tours, France
- INSERM CIC1415, CHRU Tours, Tours, France
| |
Collapse
|
9
|
Hankard A, Ingen-Housz-Oro S, El Karoui K, Paule R, Lioger B, Brihaye B, Battistella M, Jobard S, Magnant J, Diot E, Bigot A, Ferreira-Maldent N, Deriaz S, Cook AR, Henique H, Maillot F, Aouba A, Audemard-Verger A. IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series. Clin Rheumatol 2022; 41:3119-3123. [PMID: 35713822 DOI: 10.1007/s10067-022-06181-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 04/11/2022] [Accepted: 04/13/2022] [Indexed: 11/03/2022]
Abstract
OBJECTIVE There is currently no evidence of the possible benefit of plasma cell-targeting therapies (PCTT) in immunoglobulin A (IgA) monoclonal gammopathy (MG) associated with IgA vasculitis (IgAV). We report the outcome of different PCTT regimens in a cohort of MG-IgAV. METHODS We used a French network to retrospectively describe the outcome of MG-IgAV patients treated with PCTT. RESULTS Five patients were included (mean age 65 years). All patients had severe baseline presentation including extensive necrotic purpura (n = 5), gastrointestinal involvement (n = 2), peripheral neuropathies (n = 2), and glomerulonephritis (n = 1). Two patients had IgA indolent multiple myeloma and three had IgA "MG of undetermined significance." Monotypic IgA deposition in the skin vessels wall was highlighted using an immunofluorescence assay. Cases of vasculitis in three patients (n = 3) were refractory to multiple line therapies, including cyclophosphamide (n = 3) or rituximab. Finally, PCTT including bortezomib plus cyclophosphamide and dexamethasone, bortezomib plus melphalan and prednisone, or bortezomib plus lenalidomide and dexamethasone were proposed, allowing complete remission in 4/5 patients without major adverse drug events. CONCLUSION This study suggests that the MG-IgAV phenotype might be distinctive of usual IgAV (severe and refractory to conventional immunosuppressive regimens) and supports the benefit of PCTT. This study sheds new light on the overall biology of IgAV, strengthening the pathogenic role of the monoclonal IgA component in IgAV.
Collapse
Affiliation(s)
| | | | | | - Romain Paule
- Department of Internal Medicine, Hôpital Foch, Suresne, France
| | - Bertrand Lioger
- Department of Internal Medicine, Hôpital de Blois, Blois, France
| | - Benoit Brihaye
- Department of Internal Medicine, CH Saint Quentin, Saint Quentin, France
| | | | - Stéphanie Jobard
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Julie Magnant
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Elisabeth Diot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Adrien Bigot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | | | - Sophie Deriaz
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Ann-Rose Cook
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Hélène Henique
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Francois Maillot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France.,University of Tours, Tours, France
| | - Achille Aouba
- Department of Internal Medicine, CHU de Caen, Caen, France
| | - Alexandra Audemard-Verger
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France. .,University of Tours, Tours, France.
| | | |
Collapse
|
10
|
Roeser A, Moulis G, Ebbo M, Terriou L, Poullot E, Lioger B, Chilles M, Labussière-Wallet H, Mausservey C, Pha M, Puyade M, Cheze S, Limal N, Michel M, Godeau B, Mahévas M. Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia. Br J Haematol 2022; 198:595-599. [PMID: 35538740 DOI: 10.1111/bjh.18235] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 04/25/2022] [Indexed: 11/29/2022]
Affiliation(s)
- Anais Roeser
- Service de Médecine Interne, Centre de Référence des Cytopénies Auto-immunes de l'adulte, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Guillaume Moulis
- Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; CIC 1436, équipe PEPSS, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.,CIC 1436, équipe PEPSS, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Mikael Ebbo
- Service de Médecine Interne, Hôpital La Timone, CHU Marseille, Aix-Marseille Université, Marseille, France
| | - Louis Terriou
- Service de Médecine Interne et Immunologie Clinique, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Elsa Poullot
- Service d'anatomopathologie, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Bertrand Lioger
- Service de Médecine Interne, Hôpital Simone Veil, Blois, France
| | - Marie Chilles
- Service de Médecine Interne, Centre Hospitalier Régional d'Orléans, Orléans, France
| | - Helene Labussière-Wallet
- Service d'hématologie Clinique, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | | | - Micheline Pha
- Service de médecine interne, Centre de référence du lupus, syndrome des anticorps antiphospholipides et autres maladies auto-immunes rares, Groupement Hospitalier Pitié-Salpêtrière (GHPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Mathieu Puyade
- Service de Médecine Interne, Maladies infectieuses et Tropicales, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Stephane Cheze
- Institut d'Hématologie de Basse-Normandie, Centre Hospitalier Universitaire de Caen Normandie, Caen, France
| | - Nicolas Limal
- Service de Médecine Interne, Centre de Référence des Cytopénies Auto-immunes de l'adulte, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Marc Michel
- Service de Médecine Interne, Centre de Référence des Cytopénies Auto-immunes de l'adulte, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Bertrand Godeau
- Service de Médecine Interne, Centre de Référence des Cytopénies Auto-immunes de l'adulte, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Matthieu Mahévas
- Service de Médecine Interne, Centre de Référence des Cytopénies Auto-immunes de l'adulte, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| |
Collapse
|
11
|
Journaud M, Beurier P, Cohen-Aubart F, Lioger B. Sinonasal sarcoidosis with bone involvement. QJM 2022; 115:167-168. [PMID: 34931684 DOI: 10.1093/qjmed/hcab325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2021] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Journaud
- Service de Médecine Interne et Polyvalente, Centre Hospitalier Simone Veil, Mail Pierre Charlot, 41000 Blois, France
- Service de Médecine Interne et Polyvalente, Centre Hospitalier Simone Veil, Mail Pierre Charlot, 41000 Blois, France
| | - P Beurier
- INSERM UMRs 938, Centre de Recherche Saint-Antoine, Sorbonne Université, Paris 75012, France
- INSERM UMRs 938, Centre de Recherche Saint-Antoine, Sorbonne Université, Paris 75012, France
| | - F Cohen-Aubart
- Sorbonne University, Paris, Île-de-France, France and Service de Médecine Interne et Centre National de Référence Maladies Systémiques Rares et Histiocytoses, University Hospital Pitié Salpêtrière, Paris, Île-de-France, France
- Sorbonne University, Paris, Île-de-France, France and Service de Médecine Interne et Centre National de Référence Maladies Systémiques Rares et Histiocytoses, University Hospital Pitié Salpêtrière, Paris, Île-de-France, France
| | - B Lioger
- Service de Médecine Interne et Polyvalente, Centre Hospitalier Simone Veil, Mail Pierre Charlot, 41000 Blois, France
- Service de Médecine Interne et Polyvalente, Centre Hospitalier Simone Veil, Mail Pierre Charlot, 41000 Blois, France
| |
Collapse
|
12
|
Delapierre A, Terrier B, Pillebout E, Baudart P, Jourde-Chiche N, Lioger B, Martis N, Moulis G, Rivière E, Le Gouellec N, Raffray L, Urbanski G, Sanges S, Maurier F, Deroux A, Mekinian A, Monteiro R, Marcelli C, Guillevin L, Maillot F, Lucas B, Aouba A, Audemard-Verger A. Clinical phenotype and cytokine profile of adult IgA vasculitis with joint involvement. Clin Rheumatol 2022; 41:1483-1491. [PMID: 35041109 DOI: 10.1007/s10067-021-05937-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Revised: 09/01/2021] [Accepted: 09/21/2021] [Indexed: 01/03/2023]
Abstract
OBJECTIVE Joint involvement can be observed during the course of adult IgA vasculitis (IgAV). However, clinical picture, prognosis, or pathophysiological data associated with this condition have been overlooked. We aimed to describe the clinical characteristics and outcome of IgAV patients with joint involvement and look to a specific cytokine profile. METHODS We analyzed clinical and biological data from a nationwide study that included adult IgAV patients. Presentation and outcomes of patients with or without joint involvement were compared at baseline and during follow-up. Plasma cytokine measurements of IgAV patients included in a prospective study were also analyzed using multiplex assays. RESULTS Among 260 patients, 62% had joint involvement. Among them, rheumatological manifestations included arthralgia (100%) or arthritis (16%), mostly involving the knees and ankles. In multivariate analysis, patients with joint involvement, compared to those without, were younger (p = 0.002; OR 0.87; 95% CI 0.80-0.95) and showed more frequent gastrointestinal tract involvement (p = 0.012; OR = 2.08; 95% CI 1.18-3.67). However, no difference in terms of clinical response, relapse, end-stage renal disease, or death was observed between groups. Among 13 cytokines measured, plasma interleukin (IL)-1β level was higher in patients with joint involvement compared to those without (mean ± SEM IL-1β, 3.5 ± 1.2 vs. 0.47 ± 0.1 pg/ml; p = 0.024) or healthy controls (vs. 1.2 ± 0.5 pg/ml; p = 0.076). CONCLUSION Joint involvement is frequent in adult IgAV and is associated with more frequent gastrointestinal involvement. Increased plasma IL-1β levels raise the question of targeting this cytokine in patients with chronic and/or refractory joint involvement. Key Points • Joint involvement in adult IgAV is a frequent manifestation. • Joint involvement is associated with more frequent gastrointestinal manifestations. • Interleukin-1β (IL-1β) might orchestrate joint inflammation in adult IgAV. • IL-1β might be a therapeutic target in patients with chronic and/or refractory joint involvement.
Collapse
Affiliation(s)
- Alice Delapierre
- Department of Rheumatology, Normandie UNIV, UNICAEN, CHU de Caen Normandie, 14 000, Caen, France
| | - Benjamin Terrier
- Université Paris Descartes, Paris, France.,Department of Internal Medicine, Hôpital Cochin, Paris, France.,National Referral Center for Systemic and Autoimmune Diseases, Hôpital Cochin, Paris, France
| | - Evangéline Pillebout
- Department of Nephrology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Pauline Baudart
- Department of Rheumatology, Normandie UNIV, UNICAEN, CHU de Caen Normandie, 14 000, Caen, France
| | - Noémie Jourde-Chiche
- Aix-Marseille Univ, C2VN, INSERM, INRA, Centre de Néphrologie Et Transplantation Rénale, CHU de La Conception, AP-HM, Marseille, France
| | - Bertrand Lioger
- Department of Internal Medicine, Hôpital Saint Louis, APHP, Paris, France
| | - Nihal Martis
- Department of Internal Medicine, CHU, Nice, France
| | | | | | - Noémie Le Gouellec
- Department of Internal Medicine and Nephrology, Valenciennes, CH, France
| | - Loïc Raffray
- Department of Internal Medicine, CHU, La Réunion, France
| | | | - Sébastien Sanges
- Département de Médecine Interne Et Immunologie Clinique, CHU Lille, 59000, Lille, France.,Univ. Lille, INSERM, U995 - LIRIC - Lille Inflammation Research International Center, Lille, France
| | | | - Alban Deroux
- Department of Internal Medicine, CHU de Grenoble, Grenoble, France
| | - Arsène Mekinian
- Department of Internal Medicine, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Renato Monteiro
- Center of Research On Inflammation INSERM U1149, CNRS ERL8252, Paris Diderot University, Paris, France
| | - Christian Marcelli
- Department of Rheumatology, Normandie UNIV, UNICAEN, CHU de Caen Normandie, 14 000, Caen, France
| | - Loïc Guillevin
- Université Paris Descartes, Paris, France.,Department of Internal Medicine, Hôpital Cochin, Paris, France.,National Referral Center for Systemic and Autoimmune Diseases, Hôpital Cochin, Paris, France
| | - Francois Maillot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France.,University of Tours, Tours, France
| | - Bruno Lucas
- Paris Descartes University, Cochin Institute, CNRS UMR8104, INSERM U1016, Paris, France
| | - Achille Aouba
- Department of Internal Medicine and Clinical Immunology, Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000, Caen, France
| | - Alexandra Audemard-Verger
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France. .,University of Tours, Tours, France.
| | | |
Collapse
|
13
|
Roeser A, Moulis G, Ebbo M, Terriou L, Poullot E, Lioger B, Chilles M, Labussière-Wallet H, Mausservey C, Pha M, Puyade M, Cheze S, Limal N, Michel M, Godeau B, Mahevas M. Une série rétrospective multicentrique évaluant les caractéristiques, la prise en charge et l’évolution des thrombopénies amégacaryocytaires acquises. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
14
|
Nicolas S, Jouet E, Lioger B. [Climate emergency and sustainable health: What role for an internist?]. Rev Med Interne 2021; 42:821-824. [PMID: 34649756 DOI: 10.1016/j.revmed.2021.09.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 09/11/2021] [Accepted: 09/20/2021] [Indexed: 01/02/2023]
Affiliation(s)
- S Nicolas
- Service de médecine interne et polyvalente, Centre Hospitalier Simone Veil, 41000 Blois, France
| | - E Jouet
- Service de médecine interne et polyvalente, Centre Hospitalier Simone Veil, 41000 Blois, France
| | - B Lioger
- Service de médecine interne et polyvalente, Centre Hospitalier Simone Veil, 41000 Blois, France.
| |
Collapse
|
15
|
Lioger B, Le Pendu C, Mounfaloti W, Allenbach Y. [Rhabdomyolysis and anemia in a 25 year-old man]. Rev Med Interne 2021; 42:669-671. [PMID: 34456071 DOI: 10.1016/j.revmed.2021.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Accepted: 08/08/2021] [Indexed: 10/20/2022]
Affiliation(s)
- B Lioger
- Service de Médecine Interne et Maladies Systémiques, Hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude Vellefaux, Paris, France.
| | - C Le Pendu
- Service de Médecine Interne et Maladies Systémiques, Hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude Vellefaux, Paris, France
| | - W Mounfaloti
- Service de Médecine Interne et Maladies Systémiques, Hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude Vellefaux, Paris, France
| | - Y Allenbach
- Service de Médecine Interne, hôpital de la Pitié-Salpêtrière, 47-83, boulevard de l'hôpital, 75013 Paris, France
| |
Collapse
|
16
|
Mekinian A, Biard L, Dagna L, Novikov P, Salvarani C, Espita O, Sciscia S, Michaud M, Lambert M, Hernández-Rodríguez J, Schleinitz N, Awisat A, Puéchal X, Aouba A, Pons HM, Smitienko I, Gaultier JB, Edwige LM, Benhamou Y, Perlat A, Jego P, Goulenok T, Sacre K, Lioger B, Nolan H, Broner J, Dufrost V, Sene T, Seguier J, Maurier F, Berthier S, Belot A, Frikha F, Denis G, Audemard-Verger A, Pault IK, Humbert S, Woaye-Hune P, Tomelleri A, Baldissera E, Kuwana M, Logullo A, Gaches F, Zeminsky P, Galli E, Alvarado M, Luigi PB, Francesco M, Vautier M, Campochiaro C, Moiseev S, Cacoub P, Fain O, Saadoun D. Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients. Rheumatology (Oxford) 2021; 61:1376-1384. [PMID: 34363461 DOI: 10.1093/rheumatology/keab635] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 08/02/2021] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE To assess safety and efficacy of TNF-α antagonists and tocilizumab in patients with Takayasu arteritis (TAK). METHODS AND RESULTS Two-hundred nine patients with TAK [median age of 29 years [7-62], and 186 (89%) females] were included. They received either TNF-α antagonists [n = 132 (63%) with 172 lines; infliximab (n = 109), adalimumab (n = 45), golimumab (n = 8), certolizumab (n = 6) and etanercept (n = 5)], or tocilizumab [n = 77 (37%) with 121 lines; intravenous and subcutaneous in 95 and 26 cases, respectively]. A complete response at 6 months was evidenced in 101/152 (66%) on TNF-α antagonists and 75/107 (70%) on tocilizumab, respectively. Age ≥ 30 years [OR = 2.09 [1.09; 3.99]] was associated with complete response, whereas vascular signs [0.26 [0.1; 0.65]], baseline prednisone ≥ 20 mg/day [0.51 [0.28; 0.93]] were negatively associated with the complete response to TNF-α antagonists or tocilizumab. During a median follow-up of 36 months, 103 relapses were noted. Supra-aortic branches and thoracic aorta involvements [HR 2.44 (1.06; 5.65) and 3.66 (1.18; 11.4), respectively], and systemic signs at baseline [HR 2.01 (1.30; 3.11)] were significantly associated with relapse. The cumulative incidence of treatment discontinuation and relapse were similar in TNFα antagonists and tocilizumab. Fifty-eight (20%) adverse effects occurred on biological-targeted therapies of whom 37 (21%) and 21 (17%), (p= 0.4) on TNF-α antagonists and tocilizumab, respectively. CONCLUSION This large multicentre study shows high efficacy of biological-targeted treatments in refractory TAK. Efficacy, relapse and drug retention rate were equivalent with TNF-α antagonists and tocilizumab.
Collapse
Affiliation(s)
- Arsène Mekinian
- Sorbonne Université, AP-HP, Hôpital Saint Antoine, service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Paris, F-75012, France
| | - Lucie Biard
- Université de Paris, AP-HP, Hôpital Saint Louis, Service de Biostatistique et Information Médicale (DMU PRISME), INSERM U1153 Team ECSTRRA, Paris, France
| | - Lorenzo Dagna
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
| | - Pavel Novikov
- Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Carlo Salvarani
- Unit of Rheumatology, Azienda USL-IRCCS di Reggio Emilia, Italy.,Unit of Rheumatology, Università di Modena e Reggio Emilia, Italy
| | - Olivier Espita
- Service de Médecine Interne, CHU Hôtel-Dieu, Nantes, 44093, France
| | - Savino Sciscia
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Aosta Valley Network for Rare Diseases, Nephrology and Dialysis, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Martin Michaud
- Médecine Interne, Hôpital Joseph Ducuing, Toulouse, 31076
| | - Marc Lambert
- Service de médecine interne, CHU Lille, Université Lille II, Lille, France
| | - José Hernández-Rodríguez
- Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS, University of Barcelona, Barcelona, Spain )
| | | | - Abid Awisat
- Rheumatology unit, Bnai Zion medical center, Haifa, Israel
| | - Xavier Puéchal
- Université Paris Descartes, Paris, France; AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, service de médecine interne, 27 rue du Faubourg Saint-Jacques, Paris, 75014, France
| | - Achille Aouba
- Département de médecine interne, CHU, Caen, Caen, France
| | - Helene Munoz Pons
- Département de médecine interne, CHU, Saint Etienne, Saint Etienne, France
| | - Ilya Smitienko
- Rheumatology department, Medical Center, Moscow, K-31, Russia
| | - Jean Baptiste Gaultier
- Service de Médecine Interne, Hôpital Nord, Centre Hospitalier universitaire de St Etienne, saint Etienne cedex 2, 42055, France
| | - Le Mouel Edwige
- Département de médecine interne, CHU de Rennes, Rennes, France
| | - Ygal Benhamou
- Service de médecine interne, Université Rouen, CHU de Rouen, Rouen, France
| | | | - Patrick Jego
- Département de médecine interne, CHU de Rennes, Rennes, France
| | - Tiphaine Goulenok
- Département de Médecine Interne, Hôpital Bichat, Université de Paris, Assistance Publique Hôpitaux de Paris, Paris, INSERM U1149, France
| | - Karim Sacre
- Département de Médecine Interne, Hôpital Bichat, Université de Paris, Assistance Publique Hôpitaux de Paris, Paris, INSERM U1149, France
| | | | - Hassold Nolan
- Service de Rhumatologie pédiatrique et centre de référence des maladies autoinflammatoires et de l'amylose inflammatoire, CEREMAIA, hôpital de Bicêtre, APHP, France, université de Paris Sud-Saclay
| | | | - Virginie Dufrost
- University of Lorraine, Inserm UMR_S 1116, CHRU de Nancy, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, F-54000, France
| | - Thomas Sene
- Service de médecine interne, Rothschild, Paris, France
| | - Julie Seguier
- Département de médecine interne, CHU de La Timone, Marseille, France
| | - Francois Maurier
- Service de Médecine Interne et Immunologie Clinique Groupe Hospitalier UNEOS Metz-Vantoux, France
| | - Sabine Berthier
- Service de médecine interne et immunologie clinique, Université Dijon, Hôpital Dijon, Dijon, France
| | - Alexandre Belot
- Service de pédiatrie et immunologie clinique, Université Lyon, Hôpital Lyon, Lyon, France
| | - Faten Frikha
- Service de Médecine interne CHU Hédi Chaker, Route El Ain, Sfax -Faculté de Médecine de Sfax, 3029, Tunisie
| | - Guillaume Denis
- Service de médecine et d'hématologie, Hopital Rochefort, Rochefort, France
| | | | - Isabelle Kone Pault
- Service de Rhumatologie pédiatrique et centre de référence des maladies autoinflammatoires et de l'amylose inflammatoire, CEREMAIA, hôpital de Bicêtre, APHP, France, université de Paris Sud-Saclay
| | - Sebastien Humbert
- Service de médecine interne et immunologie clinique, Hôpital Besancon, Besancon, France
| | | | - Alessandro Tomelleri
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
| | - Elena Baldissera
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
| | - Masataka Kuwana
- Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
| | - Alberto Logullo
- IRCCS Centro Neurolesi "Bonino-Pulejo", Ospedale Piemonte, Messina, Italy
| | - Francis Gaches
- Médecine Interne, Hôpital Joseph Ducuing, Toulouse, 31076
| | - Pierre Zeminsky
- University of Lorraine, Inserm UMR_S 1116, CHRU de Nancy, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy, F-54000, France
| | - Elena Galli
- Unit of Rheumatology, Università di Modena e Reggio Emilia, Italy
| | - Moya Alvarado
- Unit of Rheumatology, Azienda USL-IRCCS di Reggio Emilia, Italy
| | | | | | - Mathieu Vautier
- Université de Paris, AP-HP, Hôpital Saint Louis, Service de Biostatistique et Information Médicale (DMU PRISME), INSERM U1153 Team ECSTRRA, Paris, France
| | - Corrado Campochiaro
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
| | - Sergey Moiseev
- Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Patrice Cacoub
- Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Paris, F-75013, France
| | - Olivier Fain
- Sorbonne Université, AP-HP, Hôpital Saint Antoine, service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Paris, F-75012, France
| | - David Saadoun
- Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Paris, F-75013, France
| | | |
Collapse
|
17
|
Galland J, Thoreau B, Delrue M, Neuwirth M, Stepanian A, Chauvin A, Dellal A, Nallet O, Roriz M, Devaux M, London J, Martin-Lecamp G, Froissart A, Arab N, Ferron B, Groff MH, Queyrel V, Lorut C, Regard L, Berthoux E, Bayer G, Comarmond C, Lioger B, Mekinian A, Szwebel TA, Sené T, Amador-Boreiro B, Mangin O, Sellier PO, Mouly S, Kevorkian JP, Siguret V, Vodovar D, Sene D. White blood count, D-dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID-19 patients: The French multicenter CLOTVID retrospective study. Eur J Haematol 2021; 107:190-201. [PMID: 34288162 PMCID: PMC8239942 DOI: 10.1111/ejh.13638] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2021] [Revised: 04/23/2021] [Accepted: 04/26/2021] [Indexed: 12/15/2022]
Abstract
Background A high prevalence of pulmonary embolism (PE) has been described during COVID‐19. Our aim was to identify predictive factors of PE in non‐ICU hospitalized COVID‐19 patients. Methods Data and outcomes were collected upon admission during a French multicenter retrospective study, including patients hospitalized for COVID‐19, with a CT pulmonary angiography (CTPA) performed in the emergency department for suspected PE. Predictive factors significantly associated with PE were identified through a multivariate regression model. Results A total of 88 patients (median [IQR] age of 68 years [60‐78]) were analyzed. Based on CTPA, 47 (53.4%) patients were diagnosed with PE, and 41 were not. D‐dimer ≥3000 ng/mL (OR 8.2 [95% CI] 1.3‐74.2, sensitivity (Se) 0.84, specificity (Sp) 0.78, P = .03), white blood count (WBC) ≥12.0 G/L (29.5 [2.3‐1221.2], Se 0.47, Sp 0.92, P = .02), and ferritin ≥480 µg/L (17.0 [1.7‐553.3], Se 0.96, Sp 0.44, P = .03) were independently associated with the PE diagnosis. The presence of the double criterion D‐dimer ≥3000 ng/mL and WBC ≥12.0 G/L was greatly associated with PE (OR 21.4 [4.0‐397.9], P = .004). Conclusion The white blood count, the D‐dimer and ferritin levels could be used as an indication for CTPA to confirm PE on admission in non‐ICU COVID‐19 patients.
Collapse
Affiliation(s)
- Joris Galland
- Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,University of Paris, Paris, France
| | - Benjamin Thoreau
- University of Paris, Paris, France.,Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, AP-HP, Université de Paris, Paris, France.,INSERM U1016, CNRS UMR 8104, Cochin Institute, Paris, France
| | - Maxime Delrue
- Hematology Laboratory, Lariboisière Hospital, AP-HP, University of Paris, Paris, France.,EA 3518, Paris University, Paris, France
| | - Marie Neuwirth
- Hematology Laboratory, Lariboisière Hospital, AP-HP, University of Paris, Paris, France.,INSERM UMRS U1140, Paris University, Paris, France
| | - Alain Stepanian
- Hematology Laboratory, Lariboisière Hospital, AP-HP, University of Paris, Paris, France.,EA 3518, Paris University, Paris, France
| | - Anthony Chauvin
- University of Paris, Paris, France.,Emergency Department, Lariboisière Hospital, AP-HP, University of Paris, Paris, France
| | - Azeddine Dellal
- Department of Rheumatology and Internal Medicine, Le Raincy-Montfermeil Hospital, Montfermeil, France
| | - Olivier Nallet
- Department of Cardiology, Le Raincy-Montfermeil Hospital, Montfermeil, France
| | - Melanie Roriz
- Department of Internal Medicine, Hospital Center of Agen, Agen, France
| | - Mathilde Devaux
- Department of Internal Medicine, Hospital Center of Poissy-Saint Germain, Saint Germain en Laye, France
| | - Jonathan London
- Department of Internal Medicine, Diaconesses Croix Saint-Simon Hospital, Paris, France
| | | | - Antoine Froissart
- Department of Internal Medicine, Intermunicipal Hospital Center of Créteil, Créteil, France
| | - Nouara Arab
- Department of Internal Medicine, Intermunicipal Hospital Center of Créteil, Créteil, France
| | - Bertrand Ferron
- Department of Internal Medicine, Hospital Center of Sens, Sens, France
| | - Marie-Helene Groff
- Department of Internal Medicine, Hospital Center of Nord-Mayenne, Mayenne, France
| | - Viviane Queyrel
- Department of Internal Medicine, University Hospital of Nice, Nice, France
| | - Christine Lorut
- Department of Pneumology, Cochin Hospital, AP-HP, Université de Paris, Paris, France
| | - Lucile Regard
- Department of Pneumology, Cochin Hospital, AP-HP, Université de Paris, Paris, France
| | - Emilie Berthoux
- Department of Internal Medicine, Saint Luc-Saint Joseph Hospital, Lyon, France
| | - Guillaume Bayer
- Department of Internal Medicine, Claude Galien Hospital, Quincy sous Senart, France
| | - Chloe Comarmond
- Department of Internal Medicine, Pitié-Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France.,Sorbonne University, Paris, France
| | - Bertrand Lioger
- Department of Internal Medicine, Simone Veil Hospital, Blois, France
| | - Arsène Mekinian
- Sorbonne University, Paris, France.,Department of Internal Medicine, Saint Antoine Hospital, APHP, Paris, France
| | - Tali-Anne Szwebel
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, AP-HP, Université de Paris, Paris, France
| | - Thomas Sené
- Department of Internal Medicine, Fondation Rothschild, Paris, France
| | - Blanca Amador-Boreiro
- Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,University of Paris, Paris, France
| | - Olivier Mangin
- Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,University of Paris, Paris, France
| | | | - Stephane Mouly
- Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,University of Paris, Paris, France
| | | | - Virginie Siguret
- University of Paris, Paris, France.,Hematology Laboratory, Lariboisière Hospital, AP-HP, University of Paris, Paris, France.,INSERM UMRS U1140, Paris University, Paris, France
| | | | - Dominique Vodovar
- University of Paris, Paris, France.,Centre Anti-Poison, Fernand Widal Hospital, AP-HP, University of Paris, Paris, France.,INSERM UMRS 1144, Paris, France
| | - Damien Sene
- Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.,University of Paris, Paris, France
| |
Collapse
|
18
|
Thoreau B, Galland J, Delrue M, Neuwirth M, Stepanian A, Chauvin A, Dellal A, Nallet O, Roriz M, Devaux M, London J, Martin-Lecamp G, Froissart A, Arab N, Ferron B, Groff MH, Queyrel V, Lorut C, Regard L, Berthoux E, Bayer G, Comarmond C, Lioger B, Mekinian A, Szwebel TA, Sené T, Amador-Borrero B, Mangin O, Sellier PO, Siguret V, Mouly S, Kevorkian JP, Vodovar D, Sene D. D-Dimer Level and Neutrophils Count as Predictive and Prognostic Factors of Pulmonary Embolism in Severe Non-ICU COVID-19 Patients. Viruses 2021; 13:v13050758. [PMID: 33926038 PMCID: PMC8146364 DOI: 10.3390/v13050758] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 04/23/2021] [Accepted: 04/23/2021] [Indexed: 01/08/2023] Open
Abstract
The incidence of pulmonary embolism (PE) is high during severe Coronavirus Disease 2019 (COVID-19). We aimed to identify predictive and prognostic factors of PE in non-ICU hospitalized COVID-19 patients. In the retrospective multicenter observational CLOTVID cohort, we enrolled patients with confirmed RT-PCR COVID-19 who were hospitalized in a medicine ward and also underwent a CT pulmonary angiography for a PE suspicion. Baseline data, laboratory biomarkers, treatments, and outcomes were collected. Predictive and prognostics factors of PE were identified by using logistic multivariate and by Cox regression models, respectively. A total of 174 patients were enrolled, among whom 86 (median [IQR] age of 66 years [55–77]) had post-admission PE suspicion, with 30/86 (34.9%) PE being confirmed. PE occurrence was independently associated with the lack of long-term anticoagulation or thromboprophylaxis (OR [95%CI], 72.3 [3.6–4384.8]) D-dimers ≥ 2000 ng/mL (26.3 [4.1–537.8]) and neutrophils ≥ 7.0 G/L (5.8 [1.4–29.5]). The presence of these two biomarkers was associated with a higher risk of PE (p = 0.0002) and death or ICU transfer (HR [95%CI], 12.9 [2.5–67.8], p < 0.01). In hospitalized non-ICU severe COVID-19 patients with clinical PE suspicion, the lack of anticoagulation, D-dimers ≥ 2000 ng/mL, neutrophils ≥ 7.0 G/L, and these two biomarkers combined might be useful predictive markers of PE and prognosis, respectively.
Collapse
Affiliation(s)
- Benjamin Thoreau
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, AP-HP, University of Paris, CEDEX 14, 75679 Paris, France;
- INSERM U1016, Cochin Institute, Paris, University of Paris, CNRS UMR 8104, 75014 Paris, France
- Correspondence: ; Tel.: +33-1-58-41-14-36; Fax: +33-1-58-41-14-50
| | - Joris Galland
- Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, (AP-HP) Université de Paris, 75010 Paris, France; (J.G.); (B.A.-B.); (O.M.); (S.M.); (D.S.)
| | - Maxime Delrue
- Haemostasis Laboratory, Lariboisière Hospital, AP-HP, University of Paris, 75010 Paris, France; (M.D.); (M.N.); (A.S.); (V.S.)
| | - Marie Neuwirth
- Haemostasis Laboratory, Lariboisière Hospital, AP-HP, University of Paris, 75010 Paris, France; (M.D.); (M.N.); (A.S.); (V.S.)
| | - Alain Stepanian
- Haemostasis Laboratory, Lariboisière Hospital, AP-HP, University of Paris, 75010 Paris, France; (M.D.); (M.N.); (A.S.); (V.S.)
| | - Anthony Chauvin
- Emergency Department, Lariboisière Hospital, AP-HP, University of Paris, 75010 Paris, France;
| | - Azeddine Dellal
- Department of Rheumatology and Internal Medicine, Le Raincy-Montfermeil Hospital, 93370 Montfermeil, France;
| | - Olivier Nallet
- Department of Cardiology, Le Raincy-Montfermeil Hospital, 93370 Montfermeil, France;
| | - Melanie Roriz
- Department of Internal Medicine, Hospital Center of Agen, 47923 Agen, France;
| | - Mathilde Devaux
- Department of Internal Medicine, Hospital Center of Poissy-Saint Germain, 78300 Saint Germain en Laye, France;
| | - Jonathan London
- Department of Internal Medicine, Diaconesses Croix Saint-Simon Hospital, 75012 Paris, France;
| | | | - Antoine Froissart
- Department of Internal Medicine, Intermunicipal Hospital Center of Créteil, 94000 Créteil, France; (A.F.); (N.A.)
| | - Nouara Arab
- Department of Internal Medicine, Intermunicipal Hospital Center of Créteil, 94000 Créteil, France; (A.F.); (N.A.)
| | - Bertrand Ferron
- Department of Internal Medicine, Hospital Center of Sens, 89100 Sens, France;
| | - Marie-Helene Groff
- Department of Internal Medicine, Hospital Center of Nord-Mayenne, 53100 Mayenne, France;
| | - Viviane Queyrel
- Department of Rheumatology, University Hospital of Nice, 06000 Nice, France;
| | - Christine Lorut
- Department of Pneumology, Cochin Hospital, AP-HP, Université de Paris, 75014 Paris, France; (C.L.); (L.R.)
| | - Lucile Regard
- Department of Pneumology, Cochin Hospital, AP-HP, Université de Paris, 75014 Paris, France; (C.L.); (L.R.)
| | - Emilie Berthoux
- Department of Internal Medicine, Saint Luc-Saint Joseph Hospital, 69007 Lyon, France;
| | - Guillaume Bayer
- Department of Internal Medicine, Claude Galien Hospital, 91480 Quincy sous Senart, France;
| | - Chloe Comarmond
- Department of Internal Medicine, Pitié-Salpétrière Hospital, AP-HP, Sorbonne University, 75013 Paris, France;
| | - Bertrand Lioger
- Department of Internal Medicine, Simone Veil Hospital, 41000 Blois, France;
| | - Arsène Mekinian
- Department of Internal Medicine, Saint Antoine Hospital, APHP, 75012 Paris, France;
| | - Tali-Anne Szwebel
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, AP-HP, University of Paris, CEDEX 14, 75679 Paris, France;
| | - Thomas Sené
- Department of Internal Medicine, Fondation Rothschild, 75019 Paris, France;
| | - Blanca Amador-Borrero
- Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, (AP-HP) Université de Paris, 75010 Paris, France; (J.G.); (B.A.-B.); (O.M.); (S.M.); (D.S.)
| | - Olivier Mangin
- Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, (AP-HP) Université de Paris, 75010 Paris, France; (J.G.); (B.A.-B.); (O.M.); (S.M.); (D.S.)
| | - Pierre O. Sellier
- Department of Infectious Disease, Lariboisière Hospital, APHP, 75010 Paris, France;
| | - Virginie Siguret
- Haemostasis Laboratory, Lariboisière Hospital, AP-HP, University of Paris, 75010 Paris, France; (M.D.); (M.N.); (A.S.); (V.S.)
| | - Stéphane Mouly
- Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, (AP-HP) Université de Paris, 75010 Paris, France; (J.G.); (B.A.-B.); (O.M.); (S.M.); (D.S.)
| | | | | | - Dominique Vodovar
- Centre Anti-Poison, Fernand Widal Hospital, AP-HP, University of Paris, 75010 Paris, France;
- INSERM UMRS 1144, 75006 Paris, France
| | - Damien Sene
- Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, (AP-HP) Université de Paris, 75010 Paris, France; (J.G.); (B.A.-B.); (O.M.); (S.M.); (D.S.)
| |
Collapse
|
19
|
Von Tokarski F, Hobson C, Lartigue MF, Lemaignen A, Lioger B. Streptococcus pyogenes necrotizing soft tissue infection following glucose monitoring with FreeStyle Libre device. QJM 2021; 114:58-59. [PMID: 32277817 DOI: 10.1093/qjmed/hcaa123] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- F Von Tokarski
- Department of Infectious Diseases and Internal Medicine, University Hospital of Tours, Francois Rabelais University, Tours, France
| | - C Hobson
- Department of Infectious Diseases and Internal Medicine, University Hospital of Tours, Francois Rabelais University, Tours, France
| | - M-F Lartigue
- Service de Bactériologie Virologie et Hygiène Hospitalière, University Hospital of Tours, Francois Rabelais University, Tours, France
| | - A Lemaignen
- Department of Infectious Diseases and Internal Medicine, University Hospital of Tours, Francois Rabelais University, Tours, France
| | - B Lioger
- Department of Internal Medicine, Hospital of Blois, Mail Pierre Charlot, Blois 41000, France
| |
Collapse
|
20
|
Roumier M, Le Burel S, Audia S, Chauchet A, Gousseff M, Hamidou M, Liferman F, Moulis G, Lioger B, Galicier L, Ebbo M, London J, Poutrel S, Terriou L, Zarrouk V, Michel M, Godeau B, Mahevas M. High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. Am J Hematol 2021; 96:E43-E46. [PMID: 33125750 DOI: 10.1002/ajh.26040] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Revised: 10/23/2020] [Accepted: 10/25/2020] [Indexed: 11/06/2022]
Affiliation(s)
- Mathilde Roumier
- Department of Internal Medicine, National Referral Center for Adult'Immune Cytopenias Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris Université Paris‐Est Créteil Créteil France
- Departmanet of Internal Medicine Foch Hospital Suresnes France
| | - Sébastien Le Burel
- Department of Internal Medicine, National Referral Center for Adult'Immune Cytopenias Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris Université Paris‐Est Créteil Créteil France
- Departmanet of Internal Medicine Bégin Hospital Saint‐Mandé France
| | - Sylvain Audia
- Department of Internal Medicine and Clinical Immunology Bocage Central University Hospital, CR INSERM 1098 Dijon France
| | - Adrien Chauchet
- Department of Hematology Besancon University Hospital Besancon France
| | - Marie Gousseff
- Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique Vannes France
| | - Mohammed Hamidou
- Department of Internal Medicine Hôtel Dieu University Hospital Nantes France
| | - François Liferman
- Departmanet of Internal Medicine Centre Hospitalier de Dax Dax France
| | - Guillaume Moulis
- Department of Internal Medicine Purpan University Hospital Toulouse France
| | - Bertrand Lioger
- Departmanet of Internal Medicine Saint‐Louis Hospital Paris France
| | - Lionel Galicier
- Department of Clinical Immunology Saint Louis University Hospital, Assistance Publique Hôpitaux de Paris Paris France
| | - Mickael Ebbo
- Department of Internal Medicine, La Conception Hospital, Assistance Publique Hôpitaux de Marseille Université Aix‐Marseille Marseille France
| | - Jonathan London
- Department of Internal Medicine Cochin University Hospital, Assistance Publique Hôpitaux de Paris Paris France
| | - Solène Poutrel
- Department of Internal Medicine Edouard Herriot Hospital, Hospices Civils de Lyon Lyon France
| | - Louis Terriou
- Department of Internal Medecine and Clinical Hematology Claude‐Huriez University Hospital, Université Lille Nord de France Lille France
| | - Virginie Zarrouk
- Department of Internal Medicine, Beaujon Hospital Assistance Publique Hôpitaux de Paris Clichy France
| | - Marc Michel
- Department of Internal Medicine, National Referral Center for Adult'Immune Cytopenias Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris Université Paris‐Est Créteil Créteil France
| | - Bertrand Godeau
- Department of Internal Medicine, National Referral Center for Adult'Immune Cytopenias Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris Université Paris‐Est Créteil Créteil France
| | - Matthieu Mahevas
- Department of Internal Medicine, National Referral Center for Adult'Immune Cytopenias Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris Université Paris‐Est Créteil Créteil France
| |
Collapse
|
21
|
Audemard-Verger A, Pillebout E, Amoura Z, Cacoub P, Jourde-Chiche N, Lioger B, Martis N, Moulis G, Rivière E, Baldolli A, Girard C, Goutte J, Gouellec NL, Raffray L, Urbanski G, Sanges S, Maurier F, Thervet E, Aouba A, Guillevin L, Maillot F, Terrier B. Gastrointestinal involvement in adult IgA vasculitis (Henoch-Schönlein purpura): updated picture from a French multicentre and retrospective series of 260 cases. Rheumatology (Oxford) 2021; 59:3050-3057. [PMID: 32211770 DOI: 10.1093/rheumatology/keaa104] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 01/20/2020] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES To describe the clinical presentation, treatments and prognosis of gastrointestinal (GI) involvement in adult IgA vasculitis (IgAV). METHODS Data from 260 adults with IgAV included in a French multicentre retrospective survey were analysed. Presentation and outcomes of patients with (GI+) and without (GI-) GI involvement were compared. RESULTS One hundred and thirty-seven (53%) patients had GI involvement. Initial manifestations were abdominal pain in 99%, intestinal bleeding in 31%, diarrhoea in 26% and acute surgical abdomen in only 4%. Abdominal imaging revealed thickening of intestinal wall in 61%, and endoscopies revealed abnormalities in 87%, mostly mucosal ulcerations. GI+ vs GI- patients were younger (46 ± 18 vs 54 ± 18 years; P = 0.0004), had more constitutional symptoms (43% vs 23%; P = 0.0005) and joint involvement (72 vs 50%; P = 0.0002), and higher CRP levels (3.7 vs 1.9 mg/dl; P = 0.001). Clinical response and relapse rates were comparable between groups, and all causes mortality (2 vs 4%) and IgAV-related mortality (1% vs 2%) as well. GI-related deaths were due to intestinal perforation and mesenteric ischaemia. CONCLUSION GI involvement is frequent in adult IgAV. GI involvement is frequent in adult IgAV. Mortality is not uncommon but does not seem to be specifically related to GI. Immunosuppressants should not be preferred as first-line therapy for GI+ patients but may be required in case of acute surgical abdomen.
Collapse
Affiliation(s)
| | - Evangéline Pillebout
- Department of Nephrology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP)
| | | | - Patrice Cacoub
- Department of Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpétrière.,Inflammation-Immunopathology-Biotherapy Department (DHU i2B), UMR 7211, UPMC Université Paris 06, Sorbonne Universités, Paris
| | | | - Bertrand Lioger
- Department of Internal Medicine, Hopital Saint Louis, APHP, Paris
| | | | | | | | | | | | - Julie Goutte
- Department of Internal Medicine, CHU, Saint-Etienne
| | | | - Loïc Raffray
- Department of Internal Medicine, CHU, La Réunion
| | | | - Sébastien Sanges
- Département de Médecine Interne et Immunologie Clinique, CHU.,University Lille, INSERM, U995-LIRIC-Lille Inflammation Research International Centre, Lille
| | | | - Eric Thervet
- Department of Nephrology, Hôpital Européen Georges Pompidou, AP-HP.,Université Paris Descartes
| | | | - Loïc Guillevin
- Department of Internal Medicine.,Université Paris Descartes.,National Referral Centre for Systemic and Autoimmune Diseases, Hôpital Cochin, Paris, France
| | - Francois Maillot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, University of Tours, Tours
| | - Benjamin Terrier
- Department of Internal Medicine.,Université Paris Descartes.,National Referral Centre for Systemic and Autoimmune Diseases, Hôpital Cochin, Paris, France
| | | |
Collapse
|
22
|
Audemard-Verger A, Pillebout E, Baldolli A, Gouellec NL, Augusto JF, Jourde-Chiche N, Raffray L, Thervet E, Deroux A, Goutte J, Hummel A, Lioger B, Sanges S, Cacoub P, Amoura Z, Moulis G, Maurier F, Lavigne C, Urbanski G, Chanal J, Faguer S, Deriaz S, Feirreira-Maldent N, Diot E, Maillot F, Guillevin L, Terrier B. Impact of aging on phenotype and prognosis in IgA vasculitis. Rheumatology (Oxford) 2021; 60:4245-4251. [PMID: 33410479 DOI: 10.1093/rheumatology/keaa921] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 11/19/2020] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES Immunoglobulin A vasculitis (IgAV) is a small-vessel vasculitis most frequently benign in children while the disease is more severe in adults. We aimed to study the impact of age on presentation and outcome of adult IgAV. METHODS We conducted a nationwide retrospective study including 260 IgAV patients. Patients were divided into four quartiles according to the age at IgAV diagnosis: <36; 36≤age < 52; 52≤age < 63 and ≥63 years. Comparison of presentation and outcome were performed according to age of disease onset. RESULTS Mean age at diagnosis was 50.1 ± 18 years and 63% were male. IgAV diagnosed in the lowest quartile of age was associated with more frequent joint (p< 0.0001) and gastrointestinal involvement (p= 0.001). In contrast, the oldest patients had more severe purpura with necrotic lesions (p= 0.001) and more frequent renal involvement (p< 0.0001), with more frequent hematuria, renal failure, higher urine protein excretion and more frequent tubulointerstitial lesions. Patients were treated similarly in all groups of age, and clinical response and relapse rates were similar between groups. In the 127 treated patients with follow-up data for >6 months, clinical response and relapse rates were similar between the four groups. Median follow-up was of 17.2 months (9.1-38.3 months). Renal failure at the end of follow-up was significantly more frequent in the highest quartile of age (p= 0.02), but the occurrence of end-stage renal disease was similar in all groups. Last, overall and IgAV-related deaths were associated with increase age. CONCLUSION Aging negatively impacts the severity and outcome of IgAV in adults. Younger patients have more frequent joint and gastrointestinal involvement, while old patients display more frequent severe purpura and glomerulonephritis.
Collapse
Affiliation(s)
- Alexandra Audemard-Verger
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France.,University of Tours, Tours, France
| | - Evangéline Pillebout
- Department of Nephrology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Descartes, Paris, France
| | | | - Noémie Le Gouellec
- Department of Internal Medicine and Nephrology, CH de Valenciennes, Valenciennes, France
| | | | - Noémie Jourde-Chiche
- Aix-Marseille Université, C2VN, INSERM, INRAE, Department of Nephrology, AP-HM, Marseille, France
| | - Loic Raffray
- Department of Internal Medicine, CHU de la Réunion, La Réunion, France.,Université de La Réunion, UMR Processus Infectieux en Milieu Insulaire Tropical (PIMIT), INSERM 1187, CNRS 9192, IRD 249, France La Réunion
| | - Eric Thervet
- Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France
| | - Alban Deroux
- Department of Internal Medicine, CHU de Grenoble, Grenoble, France
| | - Julie Goutte
- Department of Internal Medicine, CHU de St Etienne, St Etienne, France
| | - Aurélie Hummel
- Department of Nephrology, Hôpital Necker, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Bertrand Lioger
- Department of Internal Medicine, Hopital de Blois, Blois, France
| | - Sébastien Sanges
- CHU Lille, Département de Médecine Interne et Immunologie Clinique, France, Lille
| | - Patrice Cacoub
- Department of Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpétrière, AP-HP, Paris, France.,Inflammation-Immunopathology-Biotherapy Department (DHU i2B), UMR 7211, UPMC Université Paris 06, Sorbonne Universités, Paris, France
| | - Zahir Amoura
- Department of Internal Medicine, Hôpital Pitié-Salpétrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Guillaume Moulis
- Department of of Internal Medicine, CHU de Toulouse, Toulouse, France.,Clinical Investigation Center 1436, Toulouse University hospital, Toulouse, France
| | | | | | | | - Johan Chanal
- Department of Dermatology, Hôpital Tarnier, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Stanislas Faguer
- Department of Nephrology and Organ Transplantation, CHU de Toulouse, Toulouse, France
| | - Sophie Deriaz
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | | | - Elisabeth Diot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Francois Maillot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France.,University of Tours, Tours, France
| | - Loïc Guillevin
- Université Paris Descartes, Paris, France.,Department of Internal Medicine, Hôpital Cochin, Paris, France.,National Referral Center for Systemic and Autoimmune Diseases, Hôpital Cochin, Paris, France
| | - Benjamin Terrier
- Université Paris Descartes, Paris, France.,Department of Internal Medicine, Hôpital Cochin, Paris, France.,National Referral Center for Systemic and Autoimmune Diseases, Hôpital Cochin, Paris, France
| |
Collapse
|
23
|
Le Marec J, Henique H, Rubenstein E, Bigot A, Puyade M, Urbanski G, Lozac’h P, Allain JS, Bayer G, Fain O, Lioger B. Absence of impact of hypovitaminosis C on the bleeding phenotype of primary immune thrombocytopenia: a French prospective multicenter study. Platelets 2020; 31:1101-1103. [DOI: 10.1080/09537104.2020.1732326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Julien Le Marec
- Department of Internal Medicine, CHRU de Tours, Tours, France
| | - Hélène Henique
- Department of Internal Medicine, CHRU de Tours, Tours, France
| | - Emma Rubenstein
- Department of Internal Medicine and Systemic Diseases, Saint-Louis Hospital, Paris VII University, Paris, France
| | - Adrien Bigot
- Department of Internal Medicine, CHRU de Tours, Tours, France
| | - Mathieu Puyade
- Department of Internal Medicine, CHU de Poitiers, Poitiers, France
| | | | - Pierre Lozac’h
- Department of Internal Medicine, CHU d’Angers, Angers, France
| | - Jean-Sébastien Allain
- Department of Internal Medicine and Clinical Immunology, CHU de Rennes, Rennes, France
- Pôle CVM, Centre hospitalier de Saint Malo, France
| | - Guillaume Bayer
- Department of Internal Medicine, Claude Galien Private Hospital, Quincy-sous-Sénart, France
| | - Olivier Fain
- Department of Internal Medicine, Saint-Antoine Hospital, AP-HP, DHUi2B, Sorbonne University, Paris, France
| | - Bertrand Lioger
- Department of Internal Medicine and Systemic Diseases, Saint-Louis Hospital, Paris VII University, Paris, France
| |
Collapse
|
24
|
Mekinian A, Saadoun D, Vicaut E, Thietart S, Lioger B, Jego P, Bleibtreu A, Limal N, Connault J, Gottenberg JE, Lhorte P, Bertola JP, Delforge J, Ferreira-Maldent N, Perlat A, Talib Z, Vautier M, Savey L, Quiere I, Cacoub P, Fain O. Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Res Ther 2020; 22:218. [PMID: 32943098 PMCID: PMC7500024 DOI: 10.1186/s13075-020-02311-y] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Accepted: 09/04/2020] [Indexed: 02/03/2023] Open
Abstract
Objectives To assess long-term efficacy of tocilizumab in treatment-naive patients with Takayasu arteritis (TAK). Methods Prospective open-labeled trial in naïve patients with TAK who received steroids at the dose of 0.7 mg/kg/day and 7 infusions of 8 mg/kg/month of tocilizumab. The primary endpoint was the number of patients who discontinued steroids after 7 infusions of tocilizumab. Secondary endpoints included disease activity and the number of relapses during 18-month follow-up. Results Thirteen patients with TAK were included, with a median age of 32 years [19–45] and 12 (92%) females. Six (54%) patients met the primary end-point. A significant decrease of disease activity was observed after 6 months of tocilizumab therapy: decrease of median NIH scale (3 [3, 4] at baseline, versus 1 [0–2] after 6 months; p < 0.001), ITAS-2010 score (5 [2–7] versus 3 [0–8]; p = 0.002), and ITAS-A score (7 [4–10] versus 4 [1–15]; p = 0.0001)]. During the 12-month follow-up after tocilizumab discontinuation, a relapse occurred among 5 patients (45%) out of 11 in which achieved remission after 6 months of tocilizumab. Conclusion Tocilizumab seems an effective steroid sparing therapy in TAK, but maintenance therapy is necessary. Trial registration ClinicalTrials.gov NCT02101333. Registered on 02 April 2014.
Collapse
Affiliation(s)
- Arsene Mekinian
- Sorbonne Universités AP-HP, Hôpital Saint Antoine, service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Faculté de Médecine Sorbonne Université, F-75012, Paris, France.
| | - David Saadoun
- Sorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, National center for Autoimmune Systemic rare disease ; National center for Autoinflammatory diseases and amyloidosis, Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), INSERM, UMR_S 959, F-75013, Paris, France.,CNRS, FRE3632, F-75005, Paris, France.,CNRS, F-75013, Paris, France
| | - Eric Vicaut
- Unité de Recherche Clinique Saint-Louis-Lariboisière, APHP, Hôpital Saint Louis, Paris, France
| | - Sara Thietart
- Sorbonne Universités AP-HP, Hôpital Saint Antoine, service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Faculté de Médecine Sorbonne Université, F-75012, Paris, France
| | | | - Patrick Jego
- Service de Médecine Interne, CHU Rennes, Rennes, France
| | - Alexandre Bleibtreu
- AP-HP, service de médecine interne, Hôpital Jean Verdier, Faculté de Paris 13, 93000, Paris, France
| | - Nicolas Limal
- AP-HP, service de médecine interne, Hôpital Mondor, Université Paris Est-Créteil (UPEC), Paris, France
| | | | - Jacques-Eric Gottenberg
- Inserm UMR_1109, Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France.,Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Pauline Lhorte
- Service de Médecine Interne et vasculaire, CHU Montpellier, Montpellier, France
| | | | - Juliette Delforge
- AP-HP, service de médecine interne, Hôpital Jean Verdier, Faculté de Paris 13, 93000, Paris, France
| | | | | | - Zohra Talib
- Unité de Recherche Clinique Saint-Louis-Lariboisière, APHP, Hôpital Saint Louis, Paris, France
| | - Matthieu Vautier
- Sorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, National center for Autoimmune Systemic rare disease ; National center for Autoinflammatory diseases and amyloidosis, Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), INSERM, UMR_S 959, F-75013, Paris, France.,CNRS, FRE3632, F-75005, Paris, France.,CNRS, F-75013, Paris, France
| | - Léa Savey
- Sorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, National center for Autoimmune Systemic rare disease ; National center for Autoinflammatory diseases and amyloidosis, Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), INSERM, UMR_S 959, F-75013, Paris, France.,CNRS, FRE3632, F-75005, Paris, France.,CNRS, F-75013, Paris, France
| | - Isabelle Quiere
- Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Patrice Cacoub
- Sorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, National center for Autoimmune Systemic rare disease ; National center for Autoinflammatory diseases and amyloidosis, Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), INSERM, UMR_S 959, F-75013, Paris, France.,CNRS, FRE3632, F-75005, Paris, France.,CNRS, F-75013, Paris, France
| | - Olivier Fain
- Sorbonne Universités AP-HP, Hôpital Saint Antoine, service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Faculté de Médecine Sorbonne Université, F-75012, Paris, France
| | | |
Collapse
|
25
|
Lacasse M, Merlini T, Miquelestorena-Standley E, Maillot F, Lioger B. Pseudoaneurysmal angiolymphoid hyperplasia with eosinophilia and IgG4-related disease: A possible overlap? Presse Med 2020; 49:104019. [PMID: 32234382 DOI: 10.1016/j.lpm.2020.104019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Revised: 11/28/2018] [Accepted: 03/05/2019] [Indexed: 10/24/2022] Open
Affiliation(s)
- Marion Lacasse
- Université François-Rabelais de Tours, 37000 Tours, France; Service de médcine interne, CHRU de Tours, 37000 Tours, France
| | - Thierry Merlini
- Service de chirurgie vasculaire, CHRU de Tours, 37000 Tours, France
| | | | - François Maillot
- Université François-Rabelais de Tours, 37000 Tours, France; Service de médcine interne, CHRU de Tours, 37000 Tours, France
| | - Bertrand Lioger
- Université François-Rabelais de Tours, 37000 Tours, France; CNRS, GICC UMR 7292, 37000 Tours, France; Service de médecine interne et maladies systémiques, hôpital Saint-Louis, 75010 Paris, France.
| |
Collapse
|
26
|
Giret C, Lioger B, Tressel N, Bigot A, Maillot F. Cytopénies liées à une sitostérolémie chez une patiente de 18 ans : normalisation sous traitement. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
27
|
Bayer G, Agier MS, Lioger B, Lepelley M, Zenut M, Lanoue MC, Maillot F, Jonville-Bera AP. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. Eur J Intern Med 2019; 67:59-64. [PMID: 31279430 DOI: 10.1016/j.ejim.2019.06.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Revised: 05/13/2019] [Accepted: 06/14/2019] [Indexed: 02/06/2023]
Abstract
INTRODUCTION Rituximab induced serum sickness (RISS) is a rare delayed hypersensitivity reaction. The aim of this study was to describe the epidemiological and clinical characteristics of the RISS cases reported in France. METHOD Serum sickness cases involving rituximab were identified from the French PharmacoVigilance Database from 1998 to 2016. RESULTS We analyzed 37 cases of RISS. Rituximab was prescribed for an autoimmune disease in 78% of cases. Serum sickness occurred mainly after the first injection (54%) with a median time to onset of 12 days. The most frequent manifestations were rheumatologic symptoms (92%), fever (87%), and skin lesions (78%). The incidence was significantly higher when rituximab was used for autoimmune diseases than for a hematological malignancies. Taking into account the existence of a Systemic Lupus Erythematosus (SLE) as the indication of rituximab or as a comorbidity, the incidence of RISS in patients with SLE was even higher. DISCUSSION We report on the largest series of RISS studied to date and confirm that this reaction preferentially occurs in patients with autoimmune disease, especially SLE. This may be due to B-cell lysis, leading to the release of intracellular antigens into the serum and subsequent antigen-antibody complex formation, especially in patients with elevated autoantibody production. This could also explain why RISS often occurred after a single injection. CONCLUSION Patients generally recovered from RISS rapidly without obvious benefit from corticosteroid therapy. The risk of recurrence should prompt clinicians to question the use of rituximab after an episode of RISS.
Collapse
Affiliation(s)
- Guillaume Bayer
- CHRU de Tours, Service de médecine interne, Tours, France; Université François Rabelais, Tours, France.
| | - Marie-Sara Agier
- CHRU de Tours, Centre Régional de pharmacovigilance Centre Val de Loire, Tours, France
| | | | - Marion Lepelley
- CHRU de Grenoble, Centre Régional de pharmacovigilance, Grenoble, France
| | - Marie Zenut
- CHRU de Clermont-Ferrand, Centre Régional de pharmacovigilance, Clermont-Ferrand, France
| | | | - François Maillot
- CHRU de Tours, Service de médecine interne, Tours, France; Université François Rabelais, Tours, France
| | - Annie-Pierre Jonville-Bera
- CHRU de Tours, Centre Régional de pharmacovigilance Centre Val de Loire, Tours, France; Université de Tours, Université de Nantes, INSERM, SPHERE U1246, Tours, France
| |
Collapse
|
28
|
Desbois AC, Biard L, Sène D, Brocheriou I, Rouvier P, Lioger B, Musset L, Candon S, Zenone T, Resche-Rigon M, Piette JC, Benameur N, Cacoub P, Saadoun D. Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome. J Rheumatol 2019; 47:896-902. [PMID: 31371658 DOI: 10.3899/jrheum.190076] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/12/2019] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To report the incidence, predictors, and outcome of rituximab (RTX)-associated autoimmune disease flare. METHODS We conducted a retrospective study in a tertiary referral center from 2005 to 2015. Disease flare was defined as the onset of a new organ involvement or worsening of autoimmune disease within 4 weeks following RTX. RESULTS Among the 185 patients, we identified 7 disease flares (3.4%). All were due to type II mixed cryoglobulinemia vasculitis. Vasculitis flare occurred after a median time of 8 days (range 2-16) following RTX infusion and included acute kidney insufficiency (n = 7), purpura with cutaneous (n = 7), gastrointestinal (GI) tract involvement (n = 4), and myocarditis (n = 1). Patients with RTX-associated cryoglobulinemia vasculitis flare had these conditions more frequently: renal involvement (p = 0.0008), B cell lymphoproliferation (p = 0.015), higher level of cryoglobulin (2.1 vs 0.4 g/l, p = 0.0004), and lower level of C4 (0.02 vs 0.05, p = 0.023) compared to patients without flare after RTX (n = 43). Four patients (57%) died after a median time of 3.3 months. The 1-year survival rate was poorer in patients with vasculitis flare after RTX compared to their negative counterpart [43% (95% CI 18-100) vs 97% (95% CI 92-100), p < 0.001]. Immunofluorescence analysis of kidney biopsy in patients with worsening RTX-associated vasculitis highlighted the presence of RTX-, IgM-, and IgG1-positive staining of endomembranous deposits and thrombi within kidney lesions. CONCLUSION RTX-associated cryoglobulinemia vasculitis flare is associated with high mortality rate. We provided evidence that kidney lesions are due to immune complex deposition and to glomerular obstruction by cryoglobulinemia and RTX.
Collapse
Affiliation(s)
- Anne Claire Desbois
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Lucie Biard
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Damien Sène
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Isabelle Brocheriou
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Philippe Rouvier
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Bertrand Lioger
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Lucile Musset
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Sophie Candon
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Thierry Zenone
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Matthieu Resche-Rigon
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Jean-Charles Piette
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Neila Benameur
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - Patrice Cacoub
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors
| | - David Saadoun
- From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France. .,A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors.
| |
Collapse
|
29
|
Gras E, Terriou L, Lioger B. Thrombopénie immunologique après transplantation d’organes solides : six cas et revue de la littérature. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Lahens A, Afach S, Pendu CL, Lioger B, Mahr A. 151. DRUG-RELATED IGA VASCULITIS (HENOCH–SCHöNLEIN): A SYSTEMATIC LITERATURE REVIEW. Rheumatology (Oxford) 2019. [DOI: 10.1093/rheumatology/kez059.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Lioger B, Maillot F, Ternant D, Passot C, Paintaud G, Bejan-Angoulvant T. Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Pediatr 2019; 204:225-233.e8. [PMID: 30314658 DOI: 10.1016/j.jpeds.2018.07.065] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2018] [Revised: 07/11/2018] [Accepted: 07/13/2018] [Indexed: 01/19/2023]
Abstract
OBJECTIVES To compare the efficacy and safety of intravenous immunoglobulins (IVIG) and anti-D immunoglobulin (anti-D) in pediatric immune thrombocytopenia (ITP). STUDY DESIGN We conducted a systematic review and meta-analysis following PRISMA guidelines, including all randomized controlled trials that have assessed the efficacy and safety of anti-D and IVIG in children with ITP. We searched Medline, Embase, and Cochrane databases. Primary outcomes were the proportion of children achieving platelet count responses as defined in each study and bleeding response. Other safety outcomes included infusion reactions and hemolysis. RESULTS Eleven studies with 558 children were included. Anti-D was significantly inferior to IVIG at increasing platelet counts, both for thresholds of >20 × 109/L at 24-72 hours (response rate ratio for anti-D vs IVIG: 0.85, 95% CI 0.78-0.94) and >50 × 109/L at 24-72 hours (response rate ratio for anti-D vs IVIG: 0.75, 95% CI 0.61-0.92). Bleeding response was assessed in 4 studies, but some heterogeneity in reporting leads to unclear conclusion. General symptoms after anti-D infusion were less frequent than after IVIG (Peto OR 0.39, 95% CI 0.25-0.62). Hemolysis was more frequent after anti-D. The overall quality of the studies was low. CONCLUSIONS Compared with anti-D, IVIG led to a better response in terms of platelet count and may be preferred as a first-line treatment of ITP in children with acute hemorrhagic symptoms. However, the clinical significance of IVIG superiority on platelet count remains unclear.
Collapse
Affiliation(s)
- Bertrand Lioger
- Université François-Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France; CHRU de Tours, Service de Médecine Interne, Tours, France.
| | - François Maillot
- Université François-Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France; Université François-Rabelais de Tours, INSERM 1069, Tours, France
| | - David Ternant
- Université François-Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France; CHRU de Tours, Laboratoire de Pharmacologie-Toxicologie, Tours, France
| | - Christophe Passot
- Université François-Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France; CHRU de Tours, Laboratoire de Pharmacologie-Toxicologie, Tours, France
| | - Gilles Paintaud
- Université François-Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France; CHRU de Tours, Laboratoire de Pharmacologie-Toxicologie, Tours, France
| | - Theodora Bejan-Angoulvant
- Université François-Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France; CHRU de Tours, Service de Pharmacologie Clinique, Tours, France
| |
Collapse
|
32
|
Mausoleo A, Abou Nakad S, Le Pendu C, Mahr A, Lioger B. Maladie sérique secondaire au Rixathon® (rituximab) pour une anémie hémolytique auto-immune. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Guitton Z, Terriou L, Lega JC, Nove-Josserand R, Hie M, Amoura Z, Bussel JB, Hamidou M, Rosenthal E, Lioger B, Chauveau D, Chaminade A, Magy-Bertrand N, Michel M, Audia S, Godeau B, Mahevas M. Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology (Oxford) 2018; 57:1432-1438. [DOI: 10.1093/rheumatology/key119] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Indexed: 12/26/2022] Open
Affiliation(s)
- Zelie Guitton
- Département de Médecine Interne et Immunologie Clinique, CHU Lille, Lille, France
| | - Louis Terriou
- Département de Médecine Interne et Immunologie Clinique, CHU Lille, Lille, France
| | | | | | - Miguel Hie
- Department of Internal Medicine, Pitie-Salpetriere University Hospital, Paris, France
| | - Zahir Amoura
- Department of Internal Medicine, Pitie-Salpetriere University Hospital, Paris, France
| | | | - Mohamed Hamidou
- Department of Internal Medicine, Hôtel Dieu University Hospital, Nantes, France
| | - Eric Rosenthal
- Weill Department of Medicine, Internal Medecine, CHRU Nice, Nice, France
| | - Bertrand Lioger
- Department of Internal Medicine, Bretonneau University Hospital, Tours, France
| | | | | | | | - Marc Michel
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor Hospital, AP-HP, UPEC University, Créteil, France
| | - Sylvain Audia
- Department of Internal Medicine, Dijon University Hospital, Dijon, France
| | - Bertrand Godeau
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor Hospital, AP-HP, UPEC University, Créteil, France
| | - Matthieu Mahevas
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor Hospital, AP-HP, UPEC University, Créteil, France
| |
Collapse
|
34
|
Serris A, Amoura Z, Canouï-Poitrine F, Terrier B, Hachulla E, Costedoat-Chalumeau N, Papo T, Lambotte O, Saadoun D, Hié M, Blanche P, Lioger B, Gottenberg JE, Godeau B, Michel M. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. Am J Hematol 2018; 93:424-429. [PMID: 29247540 DOI: 10.1002/ajh.24999] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Revised: 11/30/2017] [Accepted: 12/04/2017] [Indexed: 01/19/2023]
Abstract
The aim of the study was to assess the efficacy and safety of rituximab (RTX) for treating systemic lupus erythematosus (SLE)-associated immune cytopenias. This multicenter retrospective cohort study of adults from French referral centers and networks for adult immune cytopenias and SLE involved patients ≥18 years old with a definite diagnosis of SLE treated with RTX specifically for SLE-associated immune cytopenia from 2005 to 2015. Response assessment was based on standard definitions. In total, 71 patients, 61 women (85.9%), with median age 36 years [interquartile range 31-48], were included. The median duration of SLE at the time of the first RTX administration was 6.1 years [2.6-11.6] and the reason for using RTX was immune thrombocytopenia (ITP) for 44 patients (62.0%), autoimmune hemolytic anemia (AIHA) for 16 (22.5%), Evans syndrome for 10 (14.1%), and pure red cell aplasia for one patient. Before receiving RTX, patients had received a mean of 3.1 ± 1.3 treatments that included corticosteroids (100%), and hydroxychloroquine (88.5%). The overall initial response rate to RTX was 86% (91% with ITP, 87.5% with AIHA, and 60% with Evans syndrome), including 60.5% with complete response. Median follow-up after the first injection of RTX was 26.4 months [14.3-71.2]. Among 61 initial responders, relapse occurred in 24 (39.3%); for 18, RTX retreatment was successful in 16 (88.8%). Severe infections occurred after RTX in three patients, with no fatal outcome. No cases of RTX-induced neutropenia were observed. In conclusion, RTX seems effective and relatively safe for treating SLE-associated immune cytopenias.
Collapse
Affiliation(s)
- Alexandra Serris
- AP-HP, Department of Internal Medicine; national referral center for adult's immune cytopenia, Henri-Mondor University Hospital, Université Paris-Est Créteil (UPEC); Créteil France
| | - Zahir Amoura
- AP-HP, Department of Internal Medicine; national referral center for systemic lupus, Pitié Salpêtrière University Hospital, AP-HP, Université Pierre et Marie Curie; Paris France
| | - Florence Canouï-Poitrine
- Université Paris-Est Créteil (UPEC), DHU A-TVB, IMRB, EA 7376 CEpiA (Clinical Epidemiology And Ageing Unit); Créteil F-94000 France
- Public Health Department; AP-HP, Henri-Mondor University Hospital; Créteil France
| | - Benjamin Terrier
- AP-HP, Department of Internal Medicine; National referral center for rare auto-immune and systemic diseases, Cochin University Hospital, AP-HP, Université Paris Descartes (Paris 5), INSERM U 1153; Paris France
| | - Eric Hachulla
- Department of Internal Medicine and Clinical Immunology; Claude Huriez University Hospital; Lille France
| | - Nathalie Costedoat-Chalumeau
- AP-HP, Department of Internal Medicine; National referral center for rare auto-immune and systemic diseases, Cochin University Hospital, AP-HP, Université Paris Descartes (Paris 5), INSERM U 1153; Paris France
| | - Thomas Papo
- Department of Internal Medicine; AP-HP, Bichat University Hospital; Paris France
| | - Olivier Lambotte
- Department of Internal Medicine; AP-HP, University Hospital Paris Sud; Le Kremlin Bicêtre France
| | - David Saadoun
- UPMC Universite, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Department of Internal Medicine and Clinical Immunology; referral center for rare and systemic autoimmune diseases; Paris France
| | - Miguel Hié
- Public Health Department; AP-HP, Henri-Mondor University Hospital; Créteil France
| | - Philippe Blanche
- AP-HP, Department of Internal Medicine; National referral center for rare auto-immune and systemic diseases, Cochin University Hospital, AP-HP, Université Paris Descartes (Paris 5), INSERM U 1153; Paris France
| | - Bertrand Lioger
- Department of Internal Medicine; Bretonneau University Hospital; Tours France
| | - Jacques-Eric Gottenberg
- Hautepierre University Hospital, department of Rheumatology; referral center for rare and systemic autoimmune diseases; Strasbourg France
| | - Bertrand Godeau
- AP-HP, Department of Internal Medicine; national referral center for adult's immune cytopenia, Henri-Mondor University Hospital, Université Paris-Est Créteil (UPEC); Créteil France
| | - Marc Michel
- AP-HP, Department of Internal Medicine; national referral center for adult's immune cytopenia, Henri-Mondor University Hospital, Université Paris-Est Créteil (UPEC); Créteil France
| |
Collapse
|
35
|
Mekinian A, Durtette C, Hachulla E, Lavigne C, Papo T, Zenone T, Lioger B, Deligny C, Landron C, Pouchot J, Kahn J, Fain O, Resche-Rigon M, Lambert M, De Wazieres B, Dhote R, Gondran G, Pertuiset E, Quemeneur T, Hamidou M, Sève P, Le Gallou T, Grasland A, Hatron PY. Syndrome de Cogan : étude rétrospective nationale française. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
36
|
Durtette C, Hachulla E, Resche-Rigon M, Papo T, Zénone T, Lioger B, Deligny C, Lambert M, Landron C, Pouchot J, Kahn JE, Lavigne C, De Wazieres B, Dhote R, Gondran G, Pertuiset E, Quemeneur T, Hamidou M, Sève P, Le Gallou T, Grasland A, Hatron PY, Fain O, Mekinian A. Cogan syndrome: Characteristics, outcome and treatment in a French nationwide retrospective study and literature review. Autoimmun Rev 2017; 16:1219-1223. [DOI: 10.1016/j.autrev.2017.10.005] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Accepted: 08/14/2017] [Indexed: 10/18/2022]
|
37
|
Danlos FX, Rossi GM, Blockmans D, Emmi G, Kronbichler A, Durupt S, Maynard C, Luca L, Garrouste C, Lioger B, Mourot-Cottet R, Dhote R, Arlet JB, Hanslik T, Rouvier P, Ebbo M, Puéchal X, Nochy D, Carlotti A, Mouthon L, Guillevin L, Vaglio A, Terrier B. Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome. Autoimmun Rev 2017; 16:1036-1043. [DOI: 10.1016/j.autrev.2017.07.020] [Citation(s) in RCA: 100] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 07/04/2017] [Indexed: 12/24/2022]
|
38
|
Audemard-Verger A, Terrier B, Dechartres A, Chanal J, Amoura Z, Le Gouellec N, Cacoub P, Jourde-Chiche N, Urbanski G, Augusto JF, Moulis G, Raffray L, Deroux A, Hummel A, Lioger B, Catroux M, Faguer S, Goutte J, Martis N, Maurier F, Rivière E, Sanges S, Baldolli A, Costedoat-Chalumeau N, Roriz M, Puéchal X, André M, Lavigne C, Bienvenu B, Mekinian A, Zagdoun E, Girard C, Bérezné A, Guillevin L, Thervet E, Pillebout E. Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. Arthritis Rheumatol 2017; 69:1862-1870. [DOI: 10.1002/art.40178] [Citation(s) in RCA: 94] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2016] [Accepted: 06/08/2017] [Indexed: 01/17/2023]
Affiliation(s)
- Alexandra Audemard-Verger
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes; Paris France
| | - Benjamin Terrier
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes; Paris France
| | - Agnès Dechartres
- Center for Clinical Epidemiology, Hôtel Dieu, AP-HP; Paris France
| | - Johan Chanal
- Department of Dermatology, Hôpital Tarnier, AP-HP; Paris France
| | - Zahir Amoura
- Department of Internal Medicine, Hôpital Pitié-Salpétrière, AP-HP; Paris France
| | - Noémie Le Gouellec
- Department of Internal Medicine and Nephrology, Centre Hospitalier de Valenciennes; Valenciennes France
| | - Patrice Cacoub
- Department of Internal Medicine, Hôpital Pitié-Salpétrière, AP-HP; Paris France
| | | | - Geoffrey Urbanski
- Department of Internal Medicine and Vascular Disease, Centre Hospitalier Universitaire d'Angers; Angers France
| | | | - Guillaume Moulis
- Department of Internal Medicine, Centre Hospitalier Universitaire de Toulouse; Toulouse France
| | - Loic Raffray
- Department of Internal Medicine, Centre Hospitalier Universitaire de la Réunion; Réunion France
| | - Alban Deroux
- Department of Internal Medicine, Centre Hospitalier Universitaire de Grenoble; Grenoble France
| | - Aurélie Hummel
- Department of Nephrology, Hôpital Necker, AP-HP; Paris France
| | - Bertrand Lioger
- Department of Internal Medicine, Centre Hospitalier Universitaire de Tours; Tours France
| | - Mélanie Catroux
- Department of Internal Medicine, Centre Hospitalier Universitaire de Poitiers; Poitiers France
| | - Stanislas Faguer
- Department of Nephrology and Organ Transplantation, Centre Hospitalier Universitaire de Toulouse; Toulouse France
| | - Julie Goutte
- Department of Internal Medicine, Centre Hospitalier Universitaire de St. Etienne; St. Etienne France
| | - Nihal Martis
- Department of Internal Medicine, Centre Hospitalier Universitaire de Nice; Nice France
| | - François Maurier
- Department of Internal Medicine, Hôpitaux Privés de Metz; Metz France
| | - Etienne Rivière
- Department of Internal Medicine, Centre Hospitalier Universitaire de Bordeaux; Bordeaux France
| | - Sébastien Sanges
- Centre Hospitalier Universitaire Lille, Département de Médecine Interne et Immunologie Clinique; Lille France
| | - Aurélie Baldolli
- Department of Internal Medicine, Centre Hospitalier Universitaire de Caen; Caen France
| | - Nathalie Costedoat-Chalumeau
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes; Paris France
| | - Mélanie Roriz
- Department of Internal Medicine, Centre Hospitalier Universitaire de Tours; Tours France
| | - Xavier Puéchal
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes; Paris France
| | - Marc André
- Department of Internal Medicine, Centre Hospitalier Universitaire de Clermont-Ferrand; Clermont-Ferrand France
| | - Christian Lavigne
- Department of Internal Medicine and Vascular Disease, Centre Hospitalier Universitaire d'Angers; Angers France
| | - Boris Bienvenu
- Department of Internal Medicine, Centre Hospitalier Universitaire de Caen; Caen France
| | - Arsène Mekinian
- Department of Internal Medicine, Hôpital de Bondy, AP-HP; Paris France
| | - Elie Zagdoun
- Department of Nephrology, Centre Hospitalier de St. Lo; St. Lo France
| | - Charlotte Girard
- Department of Internal Medicine, Centre Hospitalier Universitaire de Lyon; Lyon France
| | - Alice Bérezné
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes; Paris France
| | - Loïc Guillevin
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes; Paris France
| | - Eric Thervet
- Department of Nephrology, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes; Paris France
| | - Evangéline Pillebout
- Department of Nephrology, Hôpital Saint Louis, AP-HP, Université Paris Descartes; Paris France
| | | |
Collapse
|
39
|
Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer 2017. [PMID: 28646772 DOI: 10.1016/j.ejca.2017.05.032] [Citation(s) in RCA: 123] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
AIM The growing use of immune checkpoint inhibitors (ICIs) is associated with the occurrence of immune-related adverse events (irAEs). Few data are published on systemic, immunohaematological and rheumatic irAEs. In a pharmacovigilance database analysis, we screened for these irAEs and calculated their prevalence. PATIENTS AND METHODS Participants were recruited via Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie (REISAMIC)1 a French registry of grade ≥2 irAEs occurring in ICI-treated patients. The pathologies of interest were systemic autoimmune and inflammatory diseases, rheumatic diseases and immune cytopenia. RESULTS Out of 908 patients treated with anti-Programmed cell Death 1 (PD1)/anti-Programmed cell Death-Ligand 1 (PD-L1) agents (together with an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) agent in 40 cases) between December 2012 and December 2016 at a single centre, 21 patients experienced systemic irAEs. The types and the prevalence of irAEs were as follows: immune thrombocytopenia (0.2%), Sjögren syndrome (0.3%), rheumatoid arthritis (0.2%), polymyalgia rheumatica (0.2%), psoriatic arthritis (0.2%), seronegative polyarthritis (0.7%) and sarcoidosis (0.2%). Patients with Sjögren syndrome or seronegative polyarthritis were more likely to have received combination therapy with ipilimumab (2.5% for both). We described these 21 cases, together with nine additional cases from five other centres. Most irAE were moderately severe (grade 2, 63%). The median time to onset was 57°days (interquartile range (IQR) 24-117). The ICI was withdrawn in 12 cases, 25 patients (83%) received corticosteroids, and five patients (17%) received immunosuppressant/immunomodulatory agents. The irAEs resolved fully or partially in 28 cases (93%). CONCLUSION Although systemic, immunohaematological and rheumatic diseases are rarely associated with ICI use, the prevalence is higher when two ICIs are combined. Corticosteroids are often effective and may enable the continued administration of ICIs. Studies designed to identify at-risk patients are warranted.
Collapse
Affiliation(s)
- Sébastien Le Burel
- Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, F-94275 Le Kremlin-Bicêtre, France
| | - Stéphane Champiat
- Département D'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, F-94805 Villejuif, France; INSERM U981, F-94805 Villejuif, France
| | - Christine Mateus
- Département de Dermatologie, Institut Gustave Roussy, F-94805 Villejuif, France
| | - Aurélien Marabelle
- Département D'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, F-94805 Villejuif, France; INSERM U981, F-94805 Villejuif, France
| | - Jean-Marie Michot
- Département D'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, F-94805 Villejuif, France
| | - Caroline Robert
- Département de Dermatologie, Institut Gustave Roussy, F-94805 Villejuif, France
| | - Rakiba Belkhir
- Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Rhumatologie, F-94275 Le Kremlin-Bicêtre, France
| | - Jean-Charles Soria
- Département D'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, F-94805 Villejuif, France; INSERM U981, F-94805 Villejuif, France
| | - Salim Laghouati
- Unité Fonctionnelle de Pharmacovigilance, Institut Gustave Roussy, F-94805 Villejuif, France
| | - Anne-Laure Voisin
- Unité Fonctionnelle de Pharmacovigilance, Institut Gustave Roussy, F-94805 Villejuif, France
| | - Olivier Fain
- Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Antoine, Service de Médecine Interne, DHU I2B, Université Paris 6, F-75012 Paris, France
| | - Arsène Mékinian
- Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Antoine, Service de Médecine Interne, DHU I2B, Université Paris 6, F-75012 Paris, France
| | - Laetitia Coutte
- Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Service de Médecine Interne, F-75014 Paris, France
| | - Tali-Anne Szwebel
- Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Service de Médecine Interne, F-75014 Paris, France
| | - Laetitia Dunogeant
- Center Hospitalier Du Pays D'Aix, Service de Rhumatologie et Médecine Interne, F-13616 Aix en Provence, France
| | - Bertrand Lioger
- CHRU de Tours, Hôpital Bretonneau, Service de Médecine Interne, F-37044 Tours, France
| | - Cécile Luxembourger
- CHU de Toulouse, Hôpital Pierre-Paul Ricquet, Center de Rhumatologie, F-31059 Toulouse, France
| | - Xavier Mariette
- Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Rhumatologie, F-94275 Le Kremlin-Bicêtre, France; INSERM, U1184, Immunology of Viral Infections and Autoimmune Diseases, F-94276 Le Kremlin-Bicêtre, France; Université Paris Sud, UMR 1184, F-94276 Le Kremlin-Bicêtre, France
| | - Olivier Lambotte
- Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, F-94275 Le Kremlin-Bicêtre, France; INSERM, U1184, Immunology of Viral Infections and Autoimmune Diseases, F-94276 Le Kremlin-Bicêtre, France; Université Paris Sud, UMR 1184, F-94276 Le Kremlin-Bicêtre, France; CEA, DSV/iMETI, IDMIT, F-92265 Fontenay-aux-Roses, France.
| |
Collapse
|
40
|
Cabon M, Champtiaux N, Moulinet T, Meyer A, Campagne J, Lioger B, Urbanski G, Robbins A, Moulis G, Deligny C, Maurier F, Benveniste O. Myopathies nécrosantes à médiation immune à anticorps anti-SRP (ENDeMyoS) : série de 147 cas. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
41
|
Audemard A, Baldolli A, Amoura Z, Cacoub P, Sanges S, Maurier F, Lioger B, Martis N, Riviere E, Urbanski G, Pillebout E, Terrier B. Description et pronostic des atteintes digestives au cours de la vascularite à IgA de l’adulte. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
42
|
Audemard A, Baldolli A, Le Gouellec N, Raffray L, Deroux A, Goutte J, Lioger B, Amoura Z, Cacoub P, Sanges S, Pillebout E, Terrier B. Impact de l’âge sur la présentation clinique et le pronostic au cours de la vascularite à IgA de l’adulte. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
43
|
Chilles M, Merlot C, Guery T, Arar A, Ebbo M, Terriou L, Deau-Fischer B, Godeau B, Michel M, Lioger B. Amégacaryocytose acquise : série rétrospective multicentrique de dix cas. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
44
|
Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, Thibault G, Gouilleux-Gruart V, Mélet J, Paintaud G, Ternant D. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol 2017; 83:1773-1781. [PMID: 28230269 DOI: 10.1111/bcp.13270] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 01/12/2017] [Accepted: 01/25/2017] [Indexed: 12/21/2022] Open
Abstract
AIMS Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target-antigen amount, and of immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics in RA patients. METHODS In a cohort of 64 RA patients who had received repetitive courses of rituximab, the influence of CD19+ cell count, IgG serum concentration, body surface area, sex and disease activity score in 28 joints on rituximab pharmacokinetic parameters was assessed using a population pharmacokinetic analysis. RESULTS A two-compartment model, with first-order distribution and elimination best described the data. The volume of distribution of central compartment and clearance of rituximab were estimated at 4.7 l and 0.56 l day-1 , respectively. Distribution and elimination half-lives were 0.9 days and 17.3 days, respectively. As expected, the central volume of distribution increased with body surface area (P = 0.012) and was higher in male than in female (P = 0.004). We found that the elimination rate constant (k10 ) increased with CD19+ count (P = 0.00022) and IgG concentration (P = 7.4 × 10-8 ), and that k10 decreased with time (P = 0.00015), partly explained by a change in target-antigen amount. CONCLUSIONS The association between CD19+ count and k10 may be explained by target-mediated drug disposition, while the association between IgG serum concentration and k10 may be explained by a saturation of the neonatal Fc receptor at high IgG concentrations, resulting in decreased recycling of rituximab.
Collapse
Affiliation(s)
- Bertrand Lioger
- CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.,Service de Médecine Interne, CHRU de Tours, Tours, France
| | | | - Denis Mulleman
- CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.,Service de Rhumatologie, CHRU de Tours, Tours, France
| | - Christophe Passot
- CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.,Laboratoire de Pharmacologie-Toxicologie, CHRU de Tours, Tours, France
| | - Céline Desvignes
- CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.,Laboratoire de Pharmacologie-Toxicologie, CHRU de Tours, Tours, France
| | - Théodora Bejan-Angoulvant
- CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.,Service de Pharmacologie Clinique, CHRU de Tours, Tours, France
| | - Gilles Thibault
- CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.,Laboratoire d'Immunologie, CHRU de Tours, Tours, France
| | - Valérie Gouilleux-Gruart
- CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.,Laboratoire d'Immunologie, CHRU de Tours, Tours, France
| | - Julien Mélet
- CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.,Service de Rhumatologie, CHRU de Tours, Tours, France
| | - Gilles Paintaud
- CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.,Laboratoire de Pharmacologie-Toxicologie, CHRU de Tours, Tours, France
| | - David Ternant
- CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.,Laboratoire de Pharmacologie-Toxicologie, CHRU de Tours, Tours, France
| |
Collapse
|
45
|
Thoreau B, Gouaillier-Vulcain F, Machet L, Mateus C, Robert C, Ferreira-Maldent N, Maillot F, Lioger B. Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma. Acta Derm Venereol 2017; 97:408-409. [PMID: 27377178 DOI: 10.2340/00015555-2504] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Benjamin Thoreau
- Service de Medecine Interne, Hôpital Bretonneau, 2 Boulevard Tonnellé, FR-37044 Tours, France
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Weber E, Moulis G, Mahévas M, Guy C, Lioger B, Durieu I, Hunault M, Ramanantsoa M, Royer B, Default A, Pérault-Pochat MC, Moachon L, Bernard N, Bardy G, Jonville-Bera AP, Geniaux H, Godeau B, Cathébras P. Thromboses sous agonistes du récepteur de la thrombopoïétine au cours du purpura thrombopénique immunologique. Étude rétrospective multicentrique en France. Rev Med Interne 2017; 38:167-175. [DOI: 10.1016/j.revmed.2016.09.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Revised: 08/01/2016] [Accepted: 09/22/2016] [Indexed: 12/11/2022]
|
47
|
Melboucy‐Belkhir S, Khellaf M, Augier A, Boubaya M, Levy V, Le Guenno G, Terriou L, Lioger B, Ebbo M, Morin A, Chauveheid M, Michel M, Belkhir F, About F, Rose C, Moulis G, Mekinian A, Stirnemann J, Papo T, Cheze S, Rosenthal E, Viallard J, Schleinitz N, Galicier L, Adoue D, Lambotte O, Hamidou M, Godeau B, Fain O. Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. Am J Hematol 2016; 91:E499-E501. [PMID: 27528011 DOI: 10.1002/ajh.24529] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Revised: 07/26/2016] [Accepted: 08/03/2016] [Indexed: 01/19/2023]
Affiliation(s)
- Sara Melboucy‐Belkhir
- Department of Internal MedicineCentre hospitalier de Saint‐QuentinSaint‐Quentin France
| | - Mehdi Khellaf
- Department of EmergencyHenri Mondor Hospital, AP‐HP, Université Paris‐Est CréteilCréteilFrance
| | - Alexandre Augier
- Department of RadiologyAvicenne Hospital, AP‐HP, Université Paris XIIIBobignyFrance
| | - Marouane Boubaya
- Department of Clinical ResearchAvicenne Hospital, AP‐HP, Université Paris XIIIBobignyFrance
| | - Vincent Levy
- Department of Clinical ResearchAvicenne Hospital, AP‐HP, Université Paris XIIIBobignyFrance
| | - Guillaume Le Guenno
- Department of Internal MedicineEstaing University HospitalClermont FerrandFrance
| | - Louis Terriou
- Department of HematologyClaude Huriez University HospitalLilleFrance
| | - Bertrand Lioger
- Department of Internal MedicineBretonneau University HospitalToursFrance
| | - Mikaël Ebbo
- Department of Internal MedicineLa Conception Hospital, Assistance Publique Hôpitaux de Marseille, Université Aix‐MarseilleMarseilleFrance
| | - Anne‐Sophie Morin
- Jean Verdier Hospital, AP‐HP, Bondy, Université Paris XIIIBondy France
| | | | - Marc Michel
- Department of Internal MedicineHenri Mondor Hospital, AP‐HP, Université Paris‐Est CréteilCréteilFrance
| | - Farid Belkhir
- Department of Onco‐radiotherapyCentre hospitalier de Saint‐QuentinSaint‐QuentinFrance
| | - Frédégonde About
- Department of Statistics and Public HealthHenri Mondor Hospital, AP‐HP, Université Paris‐Est CréteilCréteilFrance
| | - Christian Rose
- Department of HematologySaint‐Vincent de Paul HospitalLilleFrance
| | - Guillaume Moulis
- Department of Internal MedicinePurpan University HospitalToulouseFrance
| | - Arsene Mekinian
- Department of Internal MedicineSaint Antoine Hospital, DHUi2B, University ParisVIIParis France
| | - Jérôme Stirnemann
- Department of Internal MedicineGeneva University HospitalGeneva Switzerland
| | - Thomas Papo
- Department of Internal MedicineBichat Hospital, AP‐HP, Université Paris VIIParisFrance
| | - Stéphane Cheze
- Department of HematologyClémenceau University HospitalCaenFrance
| | - Eric Rosenthal
- Department of Internal MedicineL'Archet 1 University HospitalNiceFrance
| | | | - Nicolas Schleinitz
- Department of Internal MedicineLa Conception Hospital, Assistance Publique Hôpitaux de Marseille, Université Aix‐MarseilleMarseilleFrance
| | - Lionel Galicier
- Department of Clinical ImmunologySaint Louis University HospitalParisFrance
| | - Daniel Adoue
- Department of Internal MedicinePurpan University HospitalToulouseFrance
| | - Olivier Lambotte
- Department of Internal MedicineBicêtre Hospital, AP‐HP, Université Paris SudLe Kremlin‐BicêtreFrance
| | - Mohamed Hamidou
- Department of Internal MedicineHôtel Dieu University HospitalNantesFrance
| | - Bertrand Godeau
- Department of Internal MedicineHenri Mondor Hospital, AP‐HP, Université Paris‐Est CréteilCréteilFrance
| | - Olivier Fain
- Department of Internal MedicineSaint Antoine Hospital, DHUi2B, University ParisVIIParis France
| |
Collapse
|
48
|
Grignano E, Mekinian A, Braun T, Liozon E, Hamidou M, Decaux O, Puéchal X, Kahn JE, Schoindre Y, Rossignol J, Lortholary O, Lioger B, Hermine O, Park S, Ades L, Montestruc F, Ricard L, Gardin C, Fenaux P, Fain O. Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. Leuk Res 2016; 47:136-41. [DOI: 10.1016/j.leukres.2016.05.013] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 05/13/2016] [Accepted: 05/19/2016] [Indexed: 12/26/2022]
|
49
|
Lioger B, Ferreira-Maldent N, Cottier JP, Debiais S, Gyan E, Maillot F. Rituximab for Sjögren syndrome-associated type II mixed cryoglobulinemic cerebral vasculitis. Neurol Neuroimmunol Neuroinflamm 2016; 3:e253. [PMID: 27458597 PMCID: PMC4949984 DOI: 10.1212/nxi.0000000000000253] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Accepted: 05/11/2016] [Indexed: 11/15/2022]
Affiliation(s)
- Bertrand Lioger
- Service de Médecine Interne (B.L., N.F.-M., F.M.), Service de Radiologie Générale, Diagnostique et Thérapeutique Neuroradiologie (J.P.C.), Service de Neurologie (S.D.), and Service d'Hématologie et Thérapie Cellulaire (E.G.), CHRU de Tours; CNRS UMR 7292 (B.L.), INSERM U 930 (J.P.C.), and INSERM U 1069 (F.M.), Université François Rabelais de Tours; and CIC INSERM U1415 (E.G.), Tours, France
| | - Nicole Ferreira-Maldent
- Service de Médecine Interne (B.L., N.F.-M., F.M.), Service de Radiologie Générale, Diagnostique et Thérapeutique Neuroradiologie (J.P.C.), Service de Neurologie (S.D.), and Service d'Hématologie et Thérapie Cellulaire (E.G.), CHRU de Tours; CNRS UMR 7292 (B.L.), INSERM U 930 (J.P.C.), and INSERM U 1069 (F.M.), Université François Rabelais de Tours; and CIC INSERM U1415 (E.G.), Tours, France
| | - Jean Philippe Cottier
- Service de Médecine Interne (B.L., N.F.-M., F.M.), Service de Radiologie Générale, Diagnostique et Thérapeutique Neuroradiologie (J.P.C.), Service de Neurologie (S.D.), and Service d'Hématologie et Thérapie Cellulaire (E.G.), CHRU de Tours; CNRS UMR 7292 (B.L.), INSERM U 930 (J.P.C.), and INSERM U 1069 (F.M.), Université François Rabelais de Tours; and CIC INSERM U1415 (E.G.), Tours, France
| | - Séverine Debiais
- Service de Médecine Interne (B.L., N.F.-M., F.M.), Service de Radiologie Générale, Diagnostique et Thérapeutique Neuroradiologie (J.P.C.), Service de Neurologie (S.D.), and Service d'Hématologie et Thérapie Cellulaire (E.G.), CHRU de Tours; CNRS UMR 7292 (B.L.), INSERM U 930 (J.P.C.), and INSERM U 1069 (F.M.), Université François Rabelais de Tours; and CIC INSERM U1415 (E.G.), Tours, France
| | - Emmanuel Gyan
- Service de Médecine Interne (B.L., N.F.-M., F.M.), Service de Radiologie Générale, Diagnostique et Thérapeutique Neuroradiologie (J.P.C.), Service de Neurologie (S.D.), and Service d'Hématologie et Thérapie Cellulaire (E.G.), CHRU de Tours; CNRS UMR 7292 (B.L.), INSERM U 930 (J.P.C.), and INSERM U 1069 (F.M.), Université François Rabelais de Tours; and CIC INSERM U1415 (E.G.), Tours, France
| | - François Maillot
- Service de Médecine Interne (B.L., N.F.-M., F.M.), Service de Radiologie Générale, Diagnostique et Thérapeutique Neuroradiologie (J.P.C.), Service de Neurologie (S.D.), and Service d'Hématologie et Thérapie Cellulaire (E.G.), CHRU de Tours; CNRS UMR 7292 (B.L.), INSERM U 930 (J.P.C.), and INSERM U 1069 (F.M.), Université François Rabelais de Tours; and CIC INSERM U1415 (E.G.), Tours, France
| |
Collapse
|
50
|
Lioger B, Rollin J, Vayne C, Perret-Gallix K, Pouplard C, Godeau B, Michel M, Gruel Y. No impact of PTPN22, PTPRJ and ACP1 genes polymorphisms on the risk of immune thrombocytopenia in French adult patients. Thromb Res 2016; 144:76-8. [PMID: 27309885 DOI: 10.1016/j.thromres.2016.04.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Revised: 04/14/2016] [Accepted: 04/23/2016] [Indexed: 12/19/2022]
Affiliation(s)
- Bertrand Lioger
- Service de Médecine Interne, Hôpital Bretonneau, Centre Hospitalier Universitaire (CHU) Tours, Tours, France; Unité Mixte de Recherche Centre National de la Recherche Scientifique 7292 and Université François Rabelais, Tours, France
| | - Jerome Rollin
- Unité Mixte de Recherche Centre National de la Recherche Scientifique 7292 and Université François Rabelais, Tours, France; Department of Hematology-Hemostasis, Trousseau hospital, Tours, France
| | - Caroline Vayne
- Unité Mixte de Recherche Centre National de la Recherche Scientifique 7292 and Université François Rabelais, Tours, France; Department of Hematology-Hemostasis, Trousseau hospital, Tours, France
| | - Kevin Perret-Gallix
- Unité Mixte de Recherche Centre National de la Recherche Scientifique 7292 and Université François Rabelais, Tours, France; Department of Hematology-Hemostasis, Trousseau hospital, Tours, France
| | - Claire Pouplard
- Unité Mixte de Recherche Centre National de la Recherche Scientifique 7292 and Université François Rabelais, Tours, France; Department of Hematology-Hemostasis, Trousseau hospital, Tours, France
| | - Bertrand Godeau
- Department of Internal Medicine, National Referral Centre for Adult's Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Marc Michel
- Department of Internal Medicine, National Referral Centre for Adult's Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Yves Gruel
- Unité Mixte de Recherche Centre National de la Recherche Scientifique 7292 and Université François Rabelais, Tours, France; Department of Hematology-Hemostasis, Trousseau hospital, Tours, France.
| |
Collapse
|